

FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER:
ASAHI-2-PC-1

U.S. APPLICATION NO. (if known, see 37
CFR 1.53) **09/744910**

INTERNATIONAL APPLICATION NO.:
PCT/JP99/04122

INTERNATIONAL FILING DATE:
30 JULY 1999

PRIORITY DATE CLAIMED:
31 JULY 1998

TITLE OF INVENTION: ANTIBODIES FOR DETECTING MICROORGANISMS

APPLICANT(S) FOR DO/EO/US: Kenji MATSUYAMA, Takashi SHIRAI, Takashi ETOH

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
 3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau. (see attached copy of PCT/IB/308)
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
 6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Item 11. to 16. below concern document(s) or information included:
11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 13. ☒ A **FIRST** preliminary amendment.
 14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
 15. ☐ A substitute specification.
 16. ☐ A change of power of attorney and/or address letter.
 16. ☒ Other items or information:

International Search Report
Application Data Sheet
PCT/IPEA/409 and Translation
Sequence Listing and Disk In Computer Readable Format
Receipt of Deposit of Microorganisms and Translation

U.S. APPLICATION NO. 09/744910

INTERNATIONAL APPLICATION NO.
PCT/JP99/04122ATTORNEY'S DOCKET NO.
ASAHI-2-PC-117. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee

(37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 1,000.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	13 - 20 =	0	X \$18.00	\$
Independent claims	3 - 3 =	0	X \$80.00	\$

MULTIPLE DEPENDENT CLAIMS(S) (if applicable)

+ \$270.00

\$

TOTAL OF ABOVE CALCULATIONS =

\$ 990.00

Reduction of ½ for filing by small entity, if applicable. Applicant claims Small Entity Status under 37 CFR 1.27.

+

\$

SUBTOTAL =

\$ 990.00

Processing fee of \$130 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.49(f)).

\$

TOTAL NATIONAL FEE =

\$ 990.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property+

\$

TOTAL FEES ENCLOSED =

\$ 990.00

Amount to be
refunded:

charged:

a. ☒ A check in the amount of \$ 990.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. **25-0120** in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required by 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. **25-0120**. A duplicate copy of this sheet is enclosed.

SEND ALL CORRESPONDENCE TO:

Customer No. 000466YOUNG & THOMPSON
745 South 23rd Street
2nd Floor
Arlington, VA 22202
(703) 521-2297 facsimile (703) 685-0573

January 31, 2001

By

Benoit Castel
Benoit Castel
Attorney for Applicants
Registration No. 35,041

09/744910

JC02 Rec'd PCT/PTO 31 JAN 2001
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of
Kenji MATSUYAMA et al.
Serial No. (unknown)

Filed herewith

ANTIBODIES FOR DETECTING
MICROORGANISMS

PRELIMINARY AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to the first Official Action and calculation of the filing fee, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 25, line 3, change "0.5 <5.0> %," to --5.0%--.

Page 54, line 12, change "0.5 <5.0> %," to --5.0%--.

Page 63, line 9, change "0.5 <5.0> %," to --5.0%--.

Page 84, line 15, change "0.5 <5.0> %, to --5.0%--.

Page 29, line 1, change "Ten ml," to --10 μ l--.

IN THE CLAIMS:

Claim 3, line 1, cancel "or 2".

Claim 4, line 1, cancel "or 2".

Claim 10, line 3, change "claims 1 to 8," to
--claim 1,--.

Kenji MATSUYAMA et al.

Claim 12, line 3, change "claim q to 8," to
--claim 1,--.

Claim 13, line 2, change "any one of claims 1 to 8,"
to --claim 1,--.

Respectfully submitted,

YOUNG & THOMPSON

By



Benoît Castel
Attorney for Applicants
Customer No. 000466
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

January 31, 2001



JC14 Rec'd PCT/PTO 27 AUG 2001

PCT

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Kenji MATSUYAMA et al.

Serial No. 09/744,910

GROUP Unassigned

Filed May 17, 2001

Examiner Unassigned

ANTIBODIES FOR DETECTING
MICROORGANISMS

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Notification of Defective Response
mailed July 27, 2001, please amend the above-identified
application as follows:

IN THE SPECIFICATION:

Replace the Sequence Listing previously filed with the
attached substitute Sequence Listing, attached to the present
response in paper and disk formats.

R E M A R K S


In response to the Notification of a Defective Response
mailed July 27, 2001, Applicants herewith submit a substitute
Sequence Listing, in paper and disk formats, and in compliance
with 37 CFR 1.821-1.825. Applicants hereby state that the
content of the attached paper and disc versions is the same.

It is believed that the application is now in condition
for examination on the merits.

Respectfully submitted,

YOUNG & THOMPSON

By



Andrew J. Patch
Attorney for Applicants
Registration No. 32,925
745 South 23rd Street
Arlington, VA 22202
Telephone: 521-2297

August 27, 2001

DESCRIPTION

Title of the Invention

ANTIBODIES FOR DETECTING MICROORGANISMS

5

DESCRIPTION OF BACKGROUND ART

Field of the Invention

The present invention pertains to antibodies
useful in the detection of various microorganisms,
10 particularly bacteria, and a method of detecting
microorganisms, reagent kits for detection of
microorganisms that use said antibodies, and a method
for preparing specific antibodies for detecting
microorganisms.

15 Moreover, the present invention is valuable to
the drug industry, particularly for diagnostic
medicine of microbial infections with an emphasis on
bacteria.

Prior Art

20 Diagnosis of microbial infection is confirmed by
detection of the causative pathogen from the infected
area or by detection of antibodies to the causative
pathogen in serum and body fluids. Detection of the
causative pathogen is particularly important in the
25 sense that it makes quick treatment to the patient
possible.

Detection of the causative pathogen of infections

can be generally classified as cultivation and identification methods, whereby the causative pathogen is separated and cultivated and then identified based on its biochemical properties;

5 genetic diagnosis, whereby amplification by PCR, etc., is performed based on specific genes of the causative pathogen and thus the causative pathogen is detected; or immunological methods, whereby the causative pathogen is detected using a specific
10 reaction of antibody with surface antigen marker of the causative pathogen. However, it takes time to obtain results by cultivation and identification methods or genetic diagnosis methods. Therefore, diagnosis by immunological methods is commonly used
15 because the causative pathogen can be detected within a short time with high sensitivity and the patient can be quickly and appropriately treated.

Depending on the bacterial species, a variety of marker antigens and antibodies can be used alone or,
20 in combination to detect the causative pathogen of infections by conventional immunological methods.

For instance, it is known that lipopolysaccharide (LPS), which is a genus-specific antigen of *Chlamydia*, is present as an antigen determinant
25 (Stephens, R., et al.: *J. Immunol.*, 128:1083-89, 1982, Caldwell, M.D.: *Inf. Immun.*, 44:306-14, 1984), and antibodies to LPS are used as the reagent

antibody in a variety of diagnostic kits,
particularly for the detection of *Chlamydia*
trachomatis.

Moreover, Ellena M. Peterson et al., (Infection
5 and Immunity, 59(11), 4147-4153, 1991) and Byron E.
Batteiger et al., (Infection and Immunity, 53(3),
530-533, 1986) have reported monoclonal antibodies to
major outer membrane protein (MOMP) of the genus
Chlamydia respectively.

10 Publication of unexamined Japanese patent
application No. 298/1988 discusses an immunodetection
method based on ~~the~~ western blot method that uses a
monoclonal antibody to an approximately 43 kilo
Dalton membrane protein antigen of *Mycoplasma*
15 *pneumoniae*.

Moreover, a method of preparing monoclonal
antibody to *Haemophilus influenzae* and a diagnostic
method that uses said antibody are presented in
Publication of unexamined Japanese patent application
20 No. 148859/1987 (Japanese Patent No. 64065/1994).

Proteins of approximately 20 kilo Dalton isolated
from the sodium cholate extract of the outer membrane
vesicle of *Neisseria gonorrhoeae* strain BS4 (NCTC
11922) are documented and preparation of hybridomas
25 using said substance is disclosed in British Patent
Application No. 2,172,704. Moreover, European Patent
Document no., EP 419238 A1 describes preparation of a

monoclonal antibody, which can bind to a protein of approximately 14 kilo Dalton prepared by using *Neisseria gonorrhoeae* as an immunogen and a method for the preparation of such a monoclonal antibody.

5 Additionally, a method of detecting the same *Neisseria gonorrhoeae* using monoclonal antibody to lipopolysaccharide (LPS) is mentioned in Canadian Patent Application No. 1,220,147.

10 However, there are problems with said antibodies and detection methods based on those antibodies in that species specificity to microorganisms is insufficient for proper diagnosis. The antibodies do not detect all serum types as plural surface antigens present within one species.

15 Marker antigens used in these prior arts are not standardized so that microorganisms can be detected using a same functional molecule (for instance, protein, LPS or surface polysaccharide component with the same function) which is generally present in
20 cells of various microorganisms and which changes during the course of evolution of the microorganisms as a marker, and an immunodiagnostic method based on the concept of detecting the difference in antigenicity between bacterial species using one
25 molecule as a standard is not known.

DISCLOSURE OF THE INVENTION

The present invention strives to present

antibodies to the same molecule for different microorganisms as a standard marker antigen to make ideal microorganism detection and immunodiagnosis possible, particularly antibodies to the molecular segment in the same intracellular functional component molecule for all microorganisms to be detected that changes during the course of evolution of microorganisms, a method of detecting microorganisms, which is species specific and can cover almost all serum types, a reagent kit for detection of microorganisms that use said antibody, and a method for preparing a specific antibody used for detection of microorganisms.

The present inventors discovered a protein with the same function, preserved in all microorganisms as a useful antigen protein. Usually, it is expected that a structural change of such a protein is extremely small. However, surprisingly it was found that the antigen epitope(s) of this protein has specificity to certain species or genus of microorganisms, and that the antibody for this protein not only has potentialities of being used for specifically identifying species or genus of microorganisms, but also is capable of detecting all serotypes of the target microorganisms.

The inventors focused on intracellular molecule that are present in all microbial cells and differ

between microorganisms in terms of its amino acid sequence, particularly ribosomal protein L7/L12, which is a member of ribosomal proteins. Ribosomal protein L7/L12 is a protein with a molecular weight of approximately 13 kilo Daltons and is known to exist as a ribosomal protein essential in protein synthesis. Progress has been made in understanding the complete amino acid sequence of the protein from several microorganisms including particularly *Escherichia coli* and *Baccillus subtilis*, etc., and 50 % to 65 % homology of the amino acid sequence between the microorganisms has been confirmed.

The inventors focused on the fact that even though there are similarities in said molecule between different microorganisms, this molecule also has a structural segment that is unique to each microorganism and discovered that it is possible to detect various microorganisms with species specificity and to detect all serotypes within the same species by using antibody to the protein. As a result of attempting to develop a technology for immuno-diagnosis of microorganism species using antibody specific to, for instance, *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Neisseria gonorrhoeae*, the inventors completed the present invention upon discovering that antibody specific to said protein of each species of microorganisms can be

obtained and species-specific detection of different bacteria is possible using said antibody.

The present invention relates to an antibody used for detecting microorganisms, a method of detecting
5 microorganisms using the antibody, a reagent kit for detecting microorganisms using the antibody, and a method for preparing specific antibodies for detecting microorganisms.

1) Antibodies which are antibodies to ribosomal
10 protein of microorganisms and which react specifically with said microorganisms.

2) The antibodies described in 1) above, where the ribosomal protein of the microorganisms is ribosomal protein L7/L12.

15 3) The antibodies described in 1) or 2) above, where said microorganisms are microorganisms, which cause a sexually transmitted disease (STD).

4) The antibodies described in 1) or 2) above, where said microorganisms are microorganisms which
20 cause respiratory tract infection.

5) The antibody described in 4) above, where the causative microorganisms of respiratory tract infection are microorganisms of *Haemophilus influenzae*.

25 6) The antibody described in 4) above, where the causative microorganisms of respiratory tract infection are microorganisms of *Streptococcus*

pneumoniae.

7) The antibody described in 3) above, where the causative microorganisms of sexually transmitted diseases (STD) are microorganisms of *Neisseria gonorrhoeae*.

8) The antibody described in 7) above, which is the antibody to ribosomal protein L7/L12 of *Neisseria gonorrhoeae* and which recognizes a continuous amino acid sequence moiety from 5 to 30 amino acids including the 115th alanine in the amino acid sequence of Sequence ID No. 22 of the Sequence Table.

9) A method of detecting microorganisms, which is characterized by the fact that antibody to intracellular molecules that have the same function for a variety of microorganisms is used.

10) A method of detecting microorganisms, which is characterized by the fact that any antibody described in 1) to 8) above is used.

11) A reagent kit for detecting microorganisms, which is characterized by the fact that antibody to intracellular molecules that have the same function for a variety of microorganisms is used.

12) A reagent kit for detecting microorganisms, which is characterized by the fact that any antibody described in 1) to 8) above is used.

13) A method of preparing any antibody described in 1) to 8) above, characterized by the fact that

ribosomal protein L7/L12 of microorganisms obtained by a gene manipulation procedure or by isolation from microorganisms, peptide moiety thereof, or a synthesized peptide corresponding to the peptide moiety is used as an immunogen.

The present invention will now be explained in detail.

Sequences No. 1 and No. 2 in the Sequence Table are the DNA sequence of the ribosomal protein L7/L12 gene of *Haemophilus influenzae* and corresponding amino acid sequence. Sequences No. 3 and No. 4 are the DNA sequence of the ribosomal protein L7/L12 gene of *Helicobacter pylori* and the corresponding amino acid sequence. Sequences No. 5 and No. 6 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Streptococcus pneumoniae*. Sequences No. 7 and No. 8 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Neisseria gonorrhoeae*. Sequences No. 9 and No. 10 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Neisseria meningitidis*. Sequence No. 11 and Sequence No. 12 in the Sequence Table are the primers DNA for PCR used to acquire the ribosomal protein L7/L12 gene from *Haemophilus influenzae*. Sequences No. 13 and No. 14 in the Sequence Table are the primer DNA for PCR used

to acquire the ribosomal protein L7/L12 gene from *Streptococcus pneumoniae*. Sequences No. 15 and No. 16 in the Sequence Table are the primer DNA for PCR used to acquire the ribosomal protein L7/L12 gene from *Neisseria gonorrhoeae*. Sequences No. 17 and No. 18 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Haemophilus influenzae*. Sequences No. 19 and No. 20 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Streptococcus pneumoniae*. Sequences No. 21 and No. 22 show the DNA sequence and the corresponding amino acid sequence of the ribosomal protein L7/L12 gene of *Neisseria gonorrhoeae*.

Furthermore, the left and right terminals of the amino acid sequences entered in the Sequence Table are amino group (referred to below as the N terminal) and carboxyl group terminals (referred to below as the C terminal), respectively, and the left terminal and right terminal of the base sequence is the 5' terminal and the 3' terminal, respectively.

Moreover, the series of biomolecular experiments of gene preparation mentioned in this text can be performed by methods entered in standard experimental manuals. "Molecular cloning: A laboratory manual," Cold Spring Harbor Laboratory Press, Sambrook, J. et al. (1989), is an example of the aforementioned

standard experimental manual.

The term microorganism in the present invention refers to all species of microorganisms, including bacteria, yeast, mold, *Actinomyces*, *rickettsia*, etc., but bacteria in particular, pose a problem in terms of diagnosis of microbial infections.

The term "antibody which reacts specifically with microorganisms" as used in the present invention means an antibody, which reacts specifically with a species or group of microorganisms. An antibody, which reacts specifically with a species of microorganisms, is particularly useful for the diagnosis of microbial infection diseases.

In the present invention, causative microorganisms of STD (sexually transmitted disease) include, but are not limited to, *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Candida albicans*, *Treponema pallidum*, and *Ureaplasma urealyticum*.

In the present invention, causative microorganisms of respiratory tract infection include, but are not limited to, *Haemophilus influenzae*, *Streptococcus pneumoniae*, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Streptococcus* sp. Group-A, *Mycobacterium tuberculosis*, *Legionella pneumophila*, and *Aspergillus* spp.

The term antibody in the present invention means a polyclonal antibody or monoclonal antibody that can be made using the entire length or only a partial peptide of said ribosomal protein. Although there are
5 no special restrictions to the peptide length for making the antibody, the segment should be of the length characterizing the ribosomal protein L7/L12, and a peptide of 5 amino acids or longer, particularly 8 amino acids or longer, is preferred.

10 Antiserum containing antibody (polyclonal antibody) that identifies ribosomal protein L7/L12 can be obtained by inoculating laboratory animals with adjuvant and a peptide or the full length protein as it is or when necessary, after being cross linked
15 with a carrier protein such as KLH (keyhole-limpet hemocyanin) and BSA (bovine serum albumin) and recovering the serum. Moreover, the antibody can be used after it has been purified from the antiserum.

The laboratory animals that are inoculated include
20 sheep, horses, goats, rabbits, mice, rats, etc., and sheep, rabbits, etc., are particularly preferred for preparation of polyclonal antibody. Moreover, monoclonal antibody can also be obtained by conventional methods of making hybridoma cells, but
25 mice are preferred in this case. The entire length of the said protein, or its partial peptide consisting amino acid residues of 5 or more,

preferably 8 or more, residues that has been fused with GST (glutathione S-transferase), etc., can be purified and used as antigen, or it can be used as antigen without being purified. The antibody can also be the genetic recombination antibody expressed cellularly using immunoglobulin genes that have been separated by a variety of methods in manuals ("Antibodies: A Laboratory manual," E. Harlow et al., Cold Spring Harbor Laboratory), cloning methods, etc.

Antibody to ribosomal protein L7/L12 that can be employed as the marker antigen of the present invention can be obtained by the following 3 methods, and other similar methods as well. The methods, however, are not limited to these.

a) The desired antibody can be acquired by synthesizing a peptide fragment consisting of 5-30 amino acids for microorganisms with a known ribosomal protein L7/L12 genetic sequence and amino acid sequence using the region least similar to the amino acid sequence of said protein of another microorganisms and making polyclonal antibody, or monoclonal antibody, using this peptide fragment as the immunogen.

Moreover, it is possible to acquire the entire sequence of said gene by using a conventional genetic procedure, such as gene amplification by PCR with the

DNA sequence at both terminals of said known genetic sequence as the probe, or hybridization using the sequence of a homologous segment as the template probe.

5 Then, a fused gene with another protein gene is constructed and said fused gene is inserted into the host by conventional gene insertion methods using *Escherichia coli*, etc., as the host and expressed in large quantities. The desired protein antigen can
10 then be acquired by purifying the expressed protein by affinity column methods with antibody to the protein that was used as the fusion protein. In such a case, even if antibody to the amino acid segment conserved within microorganisms is acquired, it does
15 not coincide with the purpose of the present invention because the full length of ribosomal protein L7/L12 becomes the antigen. Consequently, hybridoma that produces monoclonal antibody to the antigen that has been obtained by this method is
20 acquired by conventional methods and the desired antibody can be obtained by selecting a clone that produces antibody that will react only with the desired microorganisms.

 b) First, since there is 50 to 60% homology
25 between bacterial species in terms of their ribosomal protein L7/L12 amino acid sequence, it is possible to easily acquire said protein genes for microorganisms

with unknown L7/L12 amino acid sequence by conventional genetic procedures, such as gene amplification of a specific sequence segment by PCR methods based on the sequence of the homologous segments of the amino acid sequence, or hybridization with the homologous segments as the template probe, using bacteria having a known ribosomal protein L7/L12 amino acid sequence.

Then, a fused gene with another protein gene is constructed and said fused gene is inserted into the host by conventional gene insertion methods using *Escherichia coli*, etc., as the host and expressed in large quantities. The desired protein antigen can then be acquired by purifying the expressed protein by affinity column methods with antibody to the protein that was used as the fusion protein. In such a case, even if antibody to the amino acid segment conserved within microorganisms is acquired, it does not coincide with the purpose of the present invention because the full length of ribosomal protein L7/L12 becomes the antigen. Consequently, hybridoma that produces monoclonal antibody to the antigen that has been obtained by this method is acquired by conventional methods and the desired antibody can be obtained by selecting a clone that produces antibody that will react only with the desired microorganisms.

c) Ribosomal protein L7/L12 that has been purified to a high purity can also be obtained by another method, in the case where the amino acid sequence of the ribosomal protein L7/L12 is unknown whereby a peptide of 5 to 30 amino acids corresponding to the common sequence segment retained in the microorganisms is synthesized from the known amino acid sequence of the ribosomal protein L7/L12, and polyclonal antibody or monoclonal antibody to this peptide sequence is made by conventional methods. Then the highly purified Ribosomal protein L7/L12 from disrupted microorganisms is obtained by affinity column chromatography using said antibody.

If purity of the protein is insufficient, it can be purified by conventional methods, such as ion exchange chromatography, hydrophobic chromatography, gel filtration, etc., after which the eluted fraction of ribosomal protein L7/L12 is identified by western blotting, etc., using antibody that was made to obtain the pure fraction. The desired antibody can be obtained by acquiring hybridoma or polyclonal antibody by conventional methods using the pure ribosomal protein L7/L12 antigen that has been obtained and selecting hybridoma or polyclonal antibody that will react specifically with the desired bacteria, as in b).

The antibody of the present invention specific to

a variety of microorganisms that has been obtained by the methods in a) through c), etc., can be used in a variety of immunoassay methods to obtain diagnostic reagent kits specific to a variety of microorganisms.

5 For example, this antibody can be used in aggregation reactions where antibody is adsorbed on polystyrene latex particles, ELISA, which is a conventional technology performed in a microtiter plate, conventional immunochromatography methods, sandwich
10 assay, whereby said antibody labeled with colored particles or particles that have coloring capability, or with enzyme or phosphor, and magnetic microparticles coated with capture antibody, etc., are used, etc.

15 The term detection methods for microorganism using antibody means detection methods that use conventional immunoassay such as aggregation reactions where antibody is adsorbed on polystyrene latex particles, ELISA, which is a conventional
20 technology performed in a microtiter plate, conventional immunochromatography methods, sandwich assay, whereby said antibody labeled with colored particles or particles that have coloring capability, or with enzyme or phosphor, and magnetic
25 microparticles coated with capture antibody, etc., are used, etc.

Moreover, the optical immunoassay (OIA)

technology described in International Patent
Application Japanese Laid-open (Toku-Hyou) No.
509565/1995, in which microorganisms are detected by
an optical interference induced by an antibody
5 reaction on the optical thin film which is formed by
silicone or silicon nitride, is a useful detection
method using an antibody.

Moreover, treatment with an extraction reagent
that uses a variety of surfactants, beginning with
10 Triton X-100 and Tween-20, enzyme treatment with an
appropriate enzyme, such as protease, etc., known
methods whereby the cell structure is disrupted,
beginning with disruption of the microorganism by
physical methods, can be used to extract the
15 intracellular marker antigen from the necessary
microorganism in said detection method. However, it
is preferred that the extraction conditions be
designed using a combination of surfactants, etc., so
that the conditions are optimized for extraction of
20 each microorganism with reagents.

Moreover, the term a reagent kit for detection of
microorganisms using antibody means a reagent kit
that uses said detection method.

For instance, in the case of obtaining the
25 specific antibody to *Haemophilus influenzae*, which is
of extreme diagnostic significance as a causative
pathogen of pneumonia, bronchitis, meningitis, etc.,

the amino acid sequence and DNA sequence of ribosomal protein L7/L12 is entered in data bases, etc.

The amino acid and DNA sequence of ribosomal protein L7/L12 of *Haemophilus influenzae* are shown in
5 "Sequences No. 1 and No. 2."

Consequently, in the case of this bacteria, it is possible to similarly compare the amino acid sequence of ribosomal protein L7/L12 with the same protein of, for instance, *Helicobacter pylori*, which is shown in
10 "Sequence No. 3 and No. 4," and synthesize a peptide of 5 to 30 amino acids for the segment of low homology and make polyclonal antibody or monoclonal antibody specific to *Haemophilus influenzae* using this peptide.

15 In the case of a specific polyclonal antibody, it is preferred that IgG fraction be obtained by purification of the antiserum of immunized laboratory animals with a protein A column, etc., and affinity purification be performed with the synthetic peptide
20 used in immunization of the laboratory animals.

Moreover, PCR primers based on the sequences of N-terminal and C-terminal, for example, the PCR primers shown in Sequences No. 11 and No. 12 in the Sequence Table, were designed from the DNA sequence
25 of ribosomal protein L7/L12 of *Haemophilus influenzae*. Utilizing homology of the PCR primers, DNA fragments amplified by the PCR method or the like

using genomic DNA which is extracted from cultivated *Haemophilus influenzae* can be acquired by a conventional method. The entire length of the gene for ribosomal protein L7/L12 of *Haemophilus influenzae* can be acquired by the analysis of the DNA sequence information of these fragments.

The ribosomal protein L7/L12 gene of *Haemophilus influenzae* thus acquired forms a fusion protein gene with, for instance, GST etc., and expression vector is constructed using the appropriate expression plasmid, *Escherichia coli* is transformed and large quantities of said protein can be expressed. A suitable amount of the transformed *Escherichia coli* is cultivated and the crushed bacterial fluid that is recovered is purified by an affinity column using GST to obtain the ribosomal protein L7/L12 and GST fusion protein of *Haemophilus influenzae*. It is also possible to acquire the target specific monoclonal antibody by establishing plural hybridomas using said protein as it is or GST moiety fragments cut from the protein by protease or the like, as an antigen protein and selecting the antibody which exhibits a specific response to *Haemophilus influenzae* bacteria, or a disrupt fluid of the bacteria, or ribosomal protein L7/L12 of *Haemophilus influenzae*.

Moreover, the amino acid sequence and the DNA sequence of ribosomal protein L7/L12 of *Streptococcus*

pneumoniae which is also highly significant as a diagnostic agent for respiratory infection diseases as well as *Haemophilus influenzae*, are known from descriptions in data bases and the like. The amino

5 acid and DNA sequences of ribosomal protein L7/L12 of *Streptococcus pneumoniae* are shown in Sequences No. 5 and No. 6 of sequence table.

It is therefore possible to acquire a polyclonal antibody or monoclonal antibody which is specific to
10 *Streptococcus pneumoniae* by designing a PCR primer, the PCR primer shown by Sequence ID No. 13 or 14 in the Sequence Table, for example, based on the sequences of N-terminal and C-terminal of DNA sequence of Ribosomal Proteins L7/L12 of
15 *Streptococcus pneumoniae* in the same manner as in the case of *Haemophilus influenzae*, and processing thereafter in the same manner as in the case of *Haemophilus influenzae*.

The hybridoma AMSP-2 which produces the
20 monoclonal antibody specific to *Streptococcus pneumoniae* has been deposited with the National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Japan,
25 on July 28, 1999, with the deposition number FERM BP-6807.

Moreover, although the DNA and amino acid

sequences of the ribosomal protein L7/L12 of, for instance, *Neisseria gonorrhoeae*, which is the causative pathogen of gonorrhea and has been shown to have diagnostic significance as a typical causative pathogen of STD, were unknown, a major part of the DNA sequence and amino acid sequence, which was determined by the *Neisseria Gonorrhea Genome Project* at Oklahoma University, USA, is disclosed on the Internet.

When part of the known DNA sequence of ribosomal protein L7/L12 was used to probe the existence of DNA fragments with a similar sequence, it was found that DNA sequence corresponding to the ribosomal protein L7/L12 gene is present and it was possible to obtain data on its entire DNA sequence. The entire base sequence and corresponding amino acid sequence of the ribosomal protein L7/L12 gene of this *Neisseria gonorrhoeae* are shown in Sequences No. 7 and No. 8 of the sequence table.

It is therefore possible to acquire the target antibody which is specific to *Neisseria gonorrhoeae* having the entire or partial Ribosomal Protein L7/L12 of *Neisseria gonorrhoeae* as an antigen by designing a PCR primer, the PCR primer shown by Sequence ID No. 15 or 16 in the Sequence Table, for example, based on the sequences of N-terminal and C-terminal of DNA sequence of Ribosomal Protein L7/L12 of *Neisseria*

gonorrhoeae in the same manner as in the case of
Haemophilus influenzae, and *Streptococcus pneumoniae*,
and processing thereafter in exactly the same manner
as in the case of *Haemophilus influenzae* or
5 *Streptococcus pneumoniae*.

Particularly, the gene sequence of ribosomal
protein L7/L12 of *Neisseria meningitidis*, which
belongs to the same *Neisseria* genus as *Neisseria*
gonorrhoeae is disclosed and readily available on the
10 Internet. The entire base sequence and the
corresponding amino acid sequence of the ribosomal
protein L7/L12 gene of *Neisseria meningitidis* are
shown in "Sequences No. 9 and No. 10." Here,
comparing the entire base sequence for ribosomal
15 protein L7/L12 genes of *Neisseria meningitidis* and
Neisseria gonorrhoeae, only difference in the amino
acid sequence is that *Neisseria gonorrhoeae* has
alanine for the 115th amino acid from the N-terminal,
whereas *Neisseria meningitidis* has glutamic acid.
20 Therefore, it can be concluded that the antibody for
the ribosomal protein L7/L12 of *Neisseria gonorrhoeae*
which can specifically detects *Neisseria gonorrhoeae*
is the antibody which identifies alanine at 115 from
the N-terminal and the amino acid region including
25 the alanine of ribosomal protein L7/L12 as an
epitope.

Antibody made based on the present invention can

be used in all known types of immunoassay, such as aggregation whereby said antibody is adsorbed on polystyrene latex, ELISA, which is a conventional technology performed in a microtiter plate,

5 conventional immunochromatography, sandwich assay, whereby said antibody labeled with colored particles or particles that have coloring capability, or enzymes or phosphor, and magnetic particles coated with capture antibody are used, etc.

10 Moreover, antibody that is made based on the present invention can simultaneously function in any of these immunoassay methods as a so-called capture antibody that captures said antigen protein in solid or liquid phase and a so-called enzyme-labeled
15 antibody by modification using an enzyme, such as peroxidase and alkali phosphatase, etc., by conventional methods.

BEST MODE FOR CARRYING OUT THE INVENTION

The following examples are given to explain the
20 present invention in actual terms, the present invention not being restricted to these examples.

Example 1

Cloning of ribosomal protein L7/L12 genes from *Haemophilus influenzae*

25 After inoculating an appropriate amount of *Haemophilus influenzae* strain ATCC9334 (IID984) (obtained from Tokyo University School of Medicine

Laboratories) in a chocolate agar culture medium, the strain was cultivated for 24 hours in a CO₂ incubator under conditions of 37 °C and 0.5 <5.0> % CO₂. The colonies that grew were suspended in a TE buffer

5 (manufactured by Wako Pure Chemical Co., Ltd.) to a final concentration of approximately 5 x 10⁹ CFU/ml. Approximately 1.5 ml of this suspension was transferred to a microcentrifuge tube and centrifuged for 2 minutes at 10,000 rpm. The supernatant was

10 discarded. The sediment was resuspended in 567 µl TE buffer. Then 30 µl 10 % sodium dodecylsulfate (SDS) and 3 µl 20 mg/ml Proteinase K solution were added and thoroughly mixed. The suspension was incubated for another hour at 37 °C. Next, after adding 80 µl

15 10 % cetyl trimethyl ammonium bromide/0.7 M NaCl solution and thoroughly mixing the product, it was incubated for 10 minutes at 65 °C. Next, 700 µl chloroform-isoamyl alcohol solution at a volume ratio of 24:1 was added and stirred well. The solution was

20 centrifuged for 5 minutes (while being kept at 4 °C) at 12,000 rpm using a microcentrifugation device and the aqueous fraction was transferred to a new microtube. Isopropanol was added to the fraction at 0.6-times its volume and the tube was vigorously

25 shaken to form sediment of the DNA. The white DNA sediment was scooped with a glass rod and transferred to a different microcentrifuge tube containing 1 ml

70 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes at 10,000 rpm and the supernatant was gently removed. Then another 1 ml 70 % ethanol was added and the
5 product was centrifuged for 5 more minutes.

Once the supernatant had been removed, the sediment was dissolved in 100 µl TE buffer to obtain the DNA solution. The concentration of the genomic DNA solution was determined quantitatively according
10 to E5, Spectrophotometric determination of the amount of DNA or RNA "Molecular cloning: A laboratory manual," 1989, Eds. Sambrook, J., Fritsch, E.F., and Maniatis, T., Cold Spring Harbor Laboratory Press.

PCR (polymerase chain reaction) was performed
15 using 10 ng of this genomic DNA. Taq polymerase (Takara Co., ltd., code R001A) was employed for PCR. Then 5 µl of buffer, 4 µl dNTP mixture, and 200 pmol each of synthetic oligonucleotide-A, shown in Sequence No. 11 of the Sequence Table and synthetic
20 oligonucleotide-B, shown in Sequence No. 12 of the Sequence table were added to the enzyme to bring the final volume to 50 µl.

This mixture was cycled 5 times with a TaKaRa PCR Thermal Cycler 480 for 1 minute at 95 °C, 2 minutes
25 at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed

in 1.5 % agarose gel using some of this PCR product. This product was then stained with ethidium bromide (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp
5 cDNA. After digestion treatment with restriction endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with ethidium bromide was carried out. An approximately 370 bp band was cut out from the gel. This band was
10 purified with Suprec01 (Takara Co., Ltd.) and then inserted into pGEX-4T-1 (Pharmacia), which is a commercial vector. This same vector can function as an expression vector for the desired molecule, which can express fused protein with GST protein, by
15 insertion of the desired gene fragment into the appropriate restriction endonuclease site.

Actually, vector pGEX-4T-1 and the previous DNA were mixed together at a molar ratio of 1:3 and DNA was inserted into the vector with T4 DNA ligase
20 (Invitrogen Co.). Vector pGEX-4T-1 into which DNA had been inserted was genetically introduced to *Escherichia coli* one-shot competent cells (Invitrogen Co., Ltd.) and then inoculated in a plate of L-Broth (Takara Co., Ltd.) semi-solid culture plate containing
25 50 µg/ml ampicillin (Sigma). The plate was then set-aside at 37 °C for 12 hours and the colonies that grew were selected at random and inoculated into 2 ml

L-Broth liquid culture medium containing the same concentration of ampicillin. Shake cultivation was performed at 37 °C for 8 hours and the bacteria were recovered and the plasmid was separated using Wizard
5 Miniprep (Promega) in accordance with the attached literature. The plasmid was cleaved with restriction endonuclease BamHI/XhoI. Insertion of said PCR product was confirmed by cutting out approximately 370 bp DNA. The base sequence of the DNA that had
10 been inserted was determined using said clone.

Determination of the base sequence of the inserted DNA fragment was performed using the Fluorescence Sequencer of Applied Biosystems. The sequence sample was prepared using PRISM, Ready
15 Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems). First, 9.5 µl reaction stock solution, 4.0 µl T7 promoter primer at 0.8 pmol/µl (Gibco BRL) and 6.5 µl of template DNA for sequencing at 0.16 µg/µl were added to a microtube with a capacity of
20 0.5 ml, mixed and superposed with 100 µl mineral oil. PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 4 minutes at 60 °C. The product was then kept at 4 °C for 5 minutes. After the
25 reaction was completed, 80 µl sterilized pure water was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with

phenol-chloroform. Ten ml <microliters> 3 M sodium acetate (pH 5.2) and 300 µl ethanol were added to 100 µl aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14,000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing sample. The sequencing sample was dissolved in formamide containing 4 µl 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and applied to sequencing.

One of the 5 clones obtained had homology of the sequence with the probe used for PCR. In addition, DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example, *Neisseria gonorrhoeae*, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence ID No. 17 and No. 18 of the Sequence Table. This gene fragment clearly codes for *Haemophilus influenzae* ribosomal protein L7/L12.

Example 2

Mass expression in *Escherichia coli* and purification of ribosomal protein L7/L12 from *Haemophilus influenzae*

Fifty milliliters *Escherichia coli* into which

expression vector had been inserted were cultivated overnight in LB at 37 °C. Then 500 ml YT medium at concentration that was twice that of the
aforementioned culture was heated at 37 °C for 1
5 hour. Fifty milliliters of the *Escherichia coli* solution that had been cultivated overnight were introduced to 500 ml of the aforementioned medium. One hour later, 550 µl 100 mM isopropyl β-(D)-thiogalactopyranoside (IPTG) were introduced and
10 cultivated for 4 hours. The product was then recovered and introduced to centrifugation tube at each 250 ml and centrifuged for 10 minutes at 7,000 rpm.

The supernatant was discarded and dissolved in 25
15 ml each 50 mM Tris-HCl at a pH of 7.4 and Lysis buffer containing 25 % sucrose.

Furthermore, 1.25 ml 10 % Nonidet P-40 (NP-40) and 125 µl 1 M MgCl₂ were added and transferred to a plastic tube. Sonication was performed 1 minute x 5
20 times while ice cold. The product was centrifuged for 15 minutes at 12,000 rpm and the supernatant was recovered.

Next, the aforementioned supernatant was adsorbed on a glutathione agarose column conditioned with
25 phosphate-buffered saline (PBS).

Then the column was washed with twice the bed volume using a washing solution containing 20 mM Tris

buffer at a pH of 7.4, 4.2 mM MgCl₂, and 1 mM dithiothreitol (DTT). Elution was performed with 50 mM Tris buffer at a pH of 9.6 containing 5 mM glutathione. The protein content in the fraction was
5 determined by the pigment bonding method (Bradford method; BioRad Co.) and the main fraction was acquired.

Purity of the purified ribosomal protein L7/L12/GST fused protein that was obtained was
10 confirmed by electrophoresis to be approximately 75 %, showing that a purity satisfactory for an immunogen could be guaranteed.

Example 3

Preparation of monoclonal antibody to ribosomal 15 protein L7/L12 of *Haemophilus influenzae*

First, 100 µg fused protein antigen of ribosomal protein L7/L12/GST of *Haemophilus influenzae* were dissolved in 200 µl PBS and then 200 µl Freund's complete adjuvant were added and mixed and
20 emulsification was performed. Two-hundred microliters were injected intraperitoneally to immunize mice.

Then the same emulsion antigen was intraperitoneally injected after 2 weeks, after 4
25 weeks, and after 6 weeks. Two-fold the concentration of antigen emulsion was injected intraperitoneally after 10 weeks and after 14 weeks. The spleen was

excised 3 days after the final immunization and submitted to cell fusion.

After thoroughly mixing 2×10^7 myeloma cells per 10^8 spleen cells from mice, which had been recovered
5 aseptically, in a glass tube, the mixture was centrifuged for 5 minutes at 1,500 rpm and the supernatant was discarded. The cells were thoroughly mixed.

The myeloma cells used for cell fusion were
10 obtained by cultivation of cell strain NS-1 with an RPMI 1640 culture medium containing 10 % FCS, cultivating this product beginning 2 weeks before cell fusion using an RPMI 1640 medium containing 0.13 mM azaguanine, 0.5 μ g/ml MC-210, and 10 % FCS for 1
15 weeks, and then further cultivating the cell strain for 1 week with an RPMI 1640 medium containing 10 % FCS.

Thirty milliliters of RPMI 1640 culture medium 50 ml that had been kept at 37 °C were added to the
20 mixed cell sample and centrifuged at 1,500 rpm. After removal of the supernatant, 1 ml 50 % polyethylene glycol that had been kept at 37 °C was added and stirred for 2 minute. 10 ml RPMI 1640 medium kept at 37 °C were added and the solution was
25 vigorously mixed for approximately 5 minutes as it was suctioned and evacuated from a sterile pipette.

After centrifugation for 5 minutes at 1,000 rpm

and removal of the supernatant, 30 ml HAT medium were added to bring the cell concentration to 5×10^6 cells/ml. This mixture was stirred till uniform and then poured, 0.1 ml at a time, into a 96-well culture plate and cultivated at 37 °C under 7 % CO₂. HAT medium was added, 0.1 ml at a time, on Day 1 and at Week 1 and Week 2.

Then the cells that had produced the desired antibody were screened by ELISA.

Solutions of GST fusion ribosomal protein L7/L12 and GST protein of *Haemophilus influenzae* dissolved in PBS containing 0.05 % sodium azide diluted to 10 µg/ml were poured, each 100 µl at a time, into separate 96-well plates and adsorbed overnight at 4 °C.

After removal of the supernatant, 200 µl of 1 % bovine serum albumin solution (in PBS) were added and reacted and blocked for 1 hour at room temperature. After removal of the supernatant, the product was washed with washing solution (0.02 % Tween 20, PBS).

One-hundred microliters culture solution of fused cells were added to this and reacted for 2 hours at room temperature. The supernatant was removed and washed with washing solution. Next, 100 µl peroxidase-labeled goat anti-mouse IgG antibody solution at a concentration of 50 ng/ml were added and the solution was reacted for 1 hour at room

temperature. The supernatant was removed and the product was again washed with washing solution. Then TMB solution (KPL Co., ltd) was added, 100 μ l at a time, and the mixture was reacted for 20 minutes at room temperature. After coloration, 100 μ l 1 N sulfuric acid were added to stop the reaction and absorbance at 450 nm was determined.

As a result, positive wells that only reacted with GST fusion ribosomal protein L7/L12 and did not react with GST protein were detected, and it was concluded that antibody to ribosomal protein L7/L12 is present.

Therefore, the cells in the positive wells were recovered and cultivated with HAT medium in a 24-well plastic plate. The fused medium that had been cultivated was diluted with HT medium to a cell count of approximately 20 cells/ml and then mixed with 10^6 six-week-old mouse thyroid cells suspended in HT Cultivation medium in a 96-well culture plate.

Culture was performed for 2 weeks at 37 °C under conditions of 7 % CO₂.

Antibody activity in the culture supernatant was similarly determined by the aforementioned ELISA method and the cells that showed positive reaction with ribosomal protein L7/L12 were recovered.

Furthermore, the same dilution test and cloning procedure was repeated to obtain a total of 5 clones

of hybridoma HIRB-1 ~ 5.

Example 4

Reaction of monoclonal antibody that reacts with
ribosomal protein L7/L12 of *Haemophilus influenzae*,
5 with *Neisseria gonorrhoeae* and other microorganisms

Monoclonal antibody was produced and recovered in accordance with standard methods using the positive hybridoma cells obtained as previously described.

Basically, 5×10^6 cells that had been
10 subcultured using RPMI 1640 culture medium
(containing 10 % FCS) were intraperitoneally injected
into Balb/C mice that had been intraperitoneally
injected with 0.5 ml Pristane 2 weeks earlier.
Ascites was recovered 3 weeks later and the
15 centrifugation supernatant was obtained.

The solution containing antibody that was
obtained was adsorbed in a Protein A column (5 ml
bed, Pharmacia) and washed with 3-bed volume of PBS.
Then eluted with citrate buffer at pH 3, the antibody
20 fraction was recovered and the monoclonal antibody
produced by each hybridoma was obtained.

The monoclonal antibody derived from these 5
strains of hybridoma was used in ELISA.

The sandwich assay method was used to assess the
25 monoclonal antibody. The monoclonal antibody that
was prepared was used as an enzyme-labeled antibody
by being chemically bound to peroxidase.

That is, enzyme labeling was performed in accordance with the method in "Analytical Biochemistry" 132 (1983), 68-73 with the reagent S-acetylthioacetic acid N-hydroxysuccinimide for binding using horseradish peroxidase (Sigma Grade VI). By means of the ELISA reaction, a solution of commercial anti-*Haemophilus influenzae* polyclonal antibody which dissolved in PBS containing 0.05 % sodium azide, (Biodesign, rabbit) was diluted to a concentration of 10 µg/ml and poured, 100 µl at a time, into a separate 96-well plate and adsorbed overnight at 4 °C.

After removal of the supernatant, 200 µl 1 % FCS solution (in PBS) were added and reacted and blocked for 1 hour at room temperature. The supernatant was removed and the product was washed with washing solution (0.02 % Tween 20, PBS). One-hundred microliters of antigen solution, which had been obtained by adding Triton X-100 to culture solutions of each species of microorganism to a concentration of 0.3 % and then extracting the solution for 5 minutes at room temperature, were added to this and reacted for 2 hours at room temperature. The supernatant was removed and the product was further washed with washing solution. Then 100 µl peroxidase-labeled anti-ribosomal protein L7/L12 antibody solution at 5 µg/ml were added and reacted

for 1 hour at room temperature. The supernatant was removed and the product was washed with washing solution. TMB (KPL Co.) solution was added, 100 μ l at a time, and reacted for 20 minutes at room temperature. After coloration, 100 μ l 1 N sulfuric acid were added to stop the reaction. Absorbance at 450 nm was determined.

As a result, as shown in Table 1 it is clear that when monoclonal antibody derived from hybridoma HIRB-2 was used as the enzyme-labeled antibody, all strains of *Haemophilus influenzae* tested were detected at a sensitivity of 10^6 bacteria/ml, while reactivity of other bacteria belonging to the genus *Neisseria* and other microorganisms could not be detected, even at high concentrations of 10^8 bacteria/ml and therefore, antibody with specific reactivity to *Haemophilus influenzae* can be obtained by using monoclonal antibody to ribosomal protein L7/L12.

Table 1

Results of Detection (10 ⁶ cells/ml)		
<i>Haemophilus influenzae</i>	ATCC9327	+
<i>Haemophilus influenzae</i>	ATCC9334	+
<i>Haemophilus influenzae</i>	ATCC9007	+
<i>Haemophilus influenzae</i>	ATCC9332	+
<i>Haemophilus influenzae</i>	ATCC8142	+
<i>Haemophilus influenzae</i>	ATCC9833	+
Results of Detection (10 ⁸ cells/ml)		
<i>Neisseria meningitides</i>	ATCC13090	—
<i>Neisseria lactamica</i>	ATCC30011	—
<i>Neisseria mucosa</i>	ATCC35611	—
<i>Neisseria sicca</i>	ATCC9913	—
<i>Branhamella catarrharis</i>	ATCC25240	—
<i>Neisseria gonorrhoeae</i>	ATCC9793	—
<i>Escherichia coli</i>	ATCC25922	—
<i>Klebsiella pneumoniae</i>	ATCC13883	—

5 (+: Positive; -: Negative)

Example 5

Cloning of ribosomal protein L7/L12 genes from
Streptococcus pneumoniae, mass expression in

- 10 *Escherichia coli* and purification of the same protein
and preparation of monoclonal antibody to the same
protein

After inoculating an appropriate amount of
Streptococcus pneumoniae strain IID555 (obtained from

Tokyo University School of Medicine Laboratories) in a blood agar culture medium, the strain was cultivated for 48 hours in an incubator at 37 °C. The colonies that grew were suspended in a TE buffer to a final concentration of approximately 5×10^9 CFU/ml. Approximately 1.5 ml of this suspension was transferred to a microcentrifuge tube and centrifuged for 2 minutes at 10,000 rpm. The supernatant was discarded. The sediment was resuspended in 567 µl TE buffer. Then 30 µl 10 % SDS and 3 µl 20 mg/ml Proteinase K solution were added and thoroughly mixed. The suspension was incubated for another hour at 37 °C. Next, after adding 80 µl 10 % cetyl trimethyl ammonium bromide/0.7 M NaCl solution and thoroughly mixing the product, it was incubated for 10 minutes at 65 °C. Next, 700 µl chloroform-isoamyl alcohol solution at a volume ratio of 24:1 was added and stirred well. The solution was centrifuged for 5 minutes (while being kept at 4 °C) at 12,000 rpm using a microcentrifugation device and the aqueous fraction was transferred to a new microtube. Isopropanol was added to the fraction at 0.6-times its volume and the tube was vigorously shaken to form sediment of the DNA. The white DNA sediment was scooped with a glass rod and transferred to a different microcentrifuge tube containing 1 ml 70 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes at 10,000 rpm and the supernatant was gently removed. Then another 1 ml 70 % ethanol was added and the product was centrifuged for 5 more minutes. Once the supernatant had been removed, the sediment was dissolved in 100 µl TE buffer to obtain the DNA solution. The concentration of the genomic DNA solution was determined quantitatively in accordance with E5, Spectrophotometric determination of the amount of DNA or RNA, "Molecular cloning: A laboratory manual," 1989, Eds. Sambrook, J., Fritsch, E.F., and Maniatis, T., Cold Spring Harbor Laboratory Press.

PCR was performed using 10 ng of this genomic DNA. Taq polymerase (Takara Co., ltd., code R001A) was employed for PCR. Then 5 µl of buffer attached to enzyme, 4 µl dNTP mixture attached to enzyme, and 200 pmol each of synthetic oligonucleotide C shown in Sequence No. 13 of the Sequence Table and synthetic oligonucleotide D shown in Sequence No. 14 of the Sequence table were added to the enzyme to bring the final volume to 50 µl.

This mixture was cycled 5 times with a TaKaRa PCR Thermal Cycler 480 for 1 minute at 95 °C, 2 minutes at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed

in 1.5 % agarose gel using some of this PCR product. This product was then stained with ethidium bromide (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp

5 cDNA. After digestion treatment with restriction endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with ethidium bromide was carried out. An approximately 370 bp band was cut out from the gel. This band was
10 purified with Suprec01 (Takara Co., Ltd.) and then inserted into pGEX-6P-1 (Pharmacia), which is a commercial vector.

This same vector can function as an expression vector for the desired molecule, which can express
15 fused protein with GST protein, by insertion of the desired gene fragment into the appropriate restriction endonuclease site. Actually, vector pGEX-6P-1 and the previous DNA were mixed together at a molar ratio of 1:5 and DNA was inserted into the
20 vector with T4 DNA ligase (Invitrogen Co.). Vector pGEX-4T-1 into which DNA had been inserted was genetically introduced to *Escherichia coli* One-Shot Competent Cells (Invitrogen Co., Ltd.) and then inoculated in a plate of L-Broth (Takara Co., Ltd.)
25 semi-solid culture plate containing 50 µg/ml ampicillin (Sigma). The plate was then set aside at 37°C for 12 hours and the colonies that grew were

selected at random and inoculated into 2 ml L-Broth liquid culture medium containing the same concentration of ampicillin. Shake cultivation was performed at 37°C for 8 hours and the bacteria was recovered and the plasmid was separated using Wizard Miniprep (Promega Co.,) in accordance with the attached literature. The plasmid was cleaved with restriction endonuclease BamHI/XhoI. Insertion of said PCR product was confirmed by cutting out approximately 370 bp DNA. The base sequence of the DNA that had been inserted was determined using said clone.

Determination of the base sequence of the inserted DNA fragment was performed using the Fluorescence Sequencer of Applied Biosystems. The sequence sample was prepared using PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems). First, 9.5 µl reaction stock solution, 4.0 µl T7 promoter primer at 0.8 pmol/µl (Gibco BRL) and 6.5 µl of template DNA for sequencing at 0.16 µg/µl were added to a microtube with a capacity of 0.5 ml, mixed and superposed with 100 µl mineral oil. PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 4 minutes at 60 °C. The product was then kept at 4 °C for 5 minutes. After the reaction was completed, 80 µl sterilized pure water

was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with phenol-chloroform. Ten microliters 3 M sodium acetate (pH 5.2) and 300 μ l ethanol were added to 100 μ l aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14,000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing sample. The sequencing sample was dissolved in formamide containing 4 μ l 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and submitted to sequencing.

One of the 7 clones obtained had homology of the sequence with the probe used for PCR. In addition, DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example, *Neisseria gonorrhoeae*, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence ID No. 19 and No. 20 of the Sequence Table. This gene fragment clearly codes for *Streptococcus pneumoniae* ribosomal protein L7/L12.

50 ml *Escherichia coli* into which expression vector had been inserted was cultivated overnight in a two-fold concentration YT medium at 37 °C. Then,

450 ml of the two-fold concentration YT medium was heated at 37 °C for 1 hour. 50 ml of the *Escherichia coli* solution that had been cultivated overnight was introduced to 450 ml of the aforementioned medium.

- 5 After cultivation for one hour at 37 °C, 100 µl 500 mM IPTG was introduced and cultivated for 4 hours at 25 °C. The product was then recovered and introduced to centrifugation tube at each 250 ml and centrifuged for 20 minutes at 5000 rpm. The supernatant was
10 discarded and dissolved in 25 ml each 50 mM Tris-HCl at a pH of 7.4 and Lysis buffer containing 25 % sucrose.

- Furthermore, 1.25 ml 10 % NP-40 and 125 µl 1 M MgCl₂ were added and transferred to a plastic tube.
15 Sonication was performed 1 minute x 5 times while ice cold. The product was centrifuged for 15 minutes at 12,000 rpm and the supernatant was recovered.

- Next, the aforementioned supernatant was adsorbed on a glutathione sepharose column (manufactured by
20 Pharmacia) conditioned with PBS. Then, the column was washed with PBS three times the bed volume. Elution was performed with 50 mM Tris-HCl at a pH of 8.0 containing 10 mM glutathione. The protein content in the fraction was determined by the pigment
25 bonding method (Bradford method; BioRad Co.) and the main fraction was acquired. The main fraction was dialyzed three times against 3 L PBS.

1 ml of a cleavage buffer containing 500 mM Tris-HCl (pH 7.0), 1.5 M NaCl, 10 mM EDTA, and 10 mM DTT was added to 10 ml of 1 mg/ml solution of the resulting GST fusion ribosomal protein L7/L12. 100 μ l of 2 u/ μ l PreScission Protease (manufactured by Pharmacia company) was further added and reacted at 4 °C to separate the GST moiety from ribosomal protein L7/L12.

The reaction solution was passed through a glutathione sepharose column which had been conditioned with PBS. The solution coming out from the column was recovered. One-bed volume of PBS was passed through and also recovered. Purity of the purified ribosomal protein L7/L12 that was obtained was confirmed by electrophoresis to be approximately 90 %, showing that a purity satisfactory for an immunogen could be guaranteed.

First, 100 μ g protein antigen of ribosomal protein L7/L12 of *Streptococcus pneumoniae* was dissolved in 200 μ l PBS and then 200 μ l Freund's complete adjuvant was added and mixed and emulsification was performed. 200 μ l was intraperitoneally injected to immunize mice. Then, the same emulsion antigen was intraperitoneally injected after 2 weeks, after 4 weeks, and after 6 weeks. A two-fold concentration antigen emulsion was further injected intraperitoneally after 10 weeks and

after 14 weeks. The spleen was excised 3 days after the final immunization and submitted to cell fusion.

After thoroughly mixing 2×10^7 myeloma cells per 10^8 spleen cells from mice, which had been recovered
5 aseptically, in a glass tube, the mixture was centrifuged for 5 minutes at 1500 rpm and the supernatant was discarded. The cells were thoroughly mixed.

The myeloma cells used for cell fusion were
10 obtained by cultivation of cell strain NS-1 with an RPMI 1640 culture medium containing 10 % FCS, cultivating this product beginning 2 weeks before cell fusion using an RPMI 1640 medium containing 0.13 mM azaguanine, 0.5 μ g/ml MC-210, and 10 % FCS for 1
15 weeks, and then further cultivating the cell strain for 1 week with an RPMI 1640 medium containing 10 % FCS. 30 ml of RPMI 1640 culture medium 50 ml that had been kept at 37 °C was added to the mixed cell sample and centrifuged at 1,500 rpm. After removal of the
20 supernatant, 1 ml 50 % polyethylene glycol that had been kept at 37 °C was added and stirred for 2 minute. 10 ml RPMI 1640 medium kept at 37 °C was added and the solution was vigorously mixed for approximately 5 minutes as it was suctioned and
25 evacuated using a sterile pipette.

After centrifugation for 5 minutes at 1,000 rpm and removal of the supernatant, 30 ml HAT medium were

added to bring the cell concentration to 5×10^6 cells/ml. This mixture was stirred till uniform and then poured, 0,1ml at a time, into a 96-well culture plate and cultivated at 37 °C under 7 % CO₂. HAT
5 medium was added, 0.1 ml at a time, on Day 1 and at Week 1 and Week 2.

Then, the cells that had produced the desired antibody were screened by ELISA. Solutions of ribosomal protein L7/L12 of *Streptococcus pneumoniae*
10 dissolved in PBS containing 0.05 % sodium azide diluted to 10 µg/ml were poured, 100 µl at a time, into separate 96-well plates and adsorbed overnight at 4 °C. After removal of the supernatant, 200 µl 1 % bovine serum albumin solution (in PBS) were added and
15 reacted and blocked for 1 hour at room temperature. The supernatant was removed and the product was washed with a washing solution (0.02 % Tween 20, PBS). 100 µl of a culture solution of fusion cells was added and reacted for two hours at room
20 temperature. The supernatant was removed and the product was further washed with a washing solution. Then, 100 µl of a peroxidase-labeled goat anti-mouse antibody solution at 50 ng/ml was added and reacted for one hour at room temperature. The supernatant
25 was removed and the product was washed with a washing solution. TMB (KPL) solution was added, 100 µl at a time, and reacted for 20 minutes at room temperature.

After coloration, 100 μ l 1 N sulfuric acid were added to stop the reaction. Absorbance at 450 nm was determined.

As a result, positive wells that reacted with
5 ribosomal protein L7/L12 were detected, confirming presence of the antibody to ribosomal protein L7/L12.

Therefore, the cells in the positive wells were recovered and cultivated with HAT medium in a 24-well plastic plate. The fused medium that had been
10 cultivated was diluted with an HT medium to a cell count of approximately 20 cells/ml and then mixed with 10^6 six-week-old mouse thyroid cells suspended in the HT medium in a 96-well culture plate. The cells were cultivated for 2 weeks at 37 °C under the
15 conditions of 7 % CO₂. The antibody activity in the culture supernatant was determined by the aforementioned ELISA method and the cells that showed a positive reaction with ribosomal protein L7/L12 were recovered.

20 Furthermore, the same dilution and cloning procedure was repeated to obtain a total of 4 clones of hybridoma AMSP-1 to 4.

Example 6

Reaction of monoclonal antibody that reacts with
25 ribosomal protein L7/L12 of *Streptococcus pneumoniae*,
with *Streptococcus pneumoniae* and other
microorganisms

A monoclonal antibody was produced and recovered in accordance with standard methods using the positive hybridoma cells obtained as previously described.

5 Specifically, cells subcultured in RPMI 1640 medium (containing 10 % FCS) was diluted with a serum-free medium to about 2×10^5 cells/ml, 3.3×10^5 cells/ml, and 5×10^5 cells/ml in 25 cm² culture flasks, and the total volume was made 5 ml. After
10 cells were grown for 3 to 5 days in 7 % CO₂ at 37 °C, a flask which contains the least number of original cells was selected among flasks in which cells were grown. The same procedure was repeated until the cells diluted to 2×10^5 cells/ml grow to 2×10^6
15 cells/ml in 3 to 4 days, thereby adapting the cells with the serum-free medium. Next, cloning was performed in a 96-well plate for bacteria cultivation to select cells exhibiting fastest growth and a highest antibody titer. The selected cells were
20 grown in a 24-well plate and diluted with a serum-free medium in a 25 cm² culture flask to a concentration of about 2×10^5 cells/ml and the total volume was made 10 ml. After incubation for 3 to 4 days in 7 % CO₂ at 37 °C to a concentration of 1×10^6
25 cells/ml, the culture broth 100 ml, 1×10^6 cells/ml was transferred to a bottle for mass cultivation which were grown in the same manner in a 75 cm²

flask. 100 ml of a serum-free medium was added to the mixture, which was incubated at 37 °C for two days while stirring. 200 ml of the serum-free medium was added again and the mixture was incubated for a further two days. The culture broth was divided into four aliquot, the serum-free medium was added to each portion, followed by incubation for two days. After further addition of 400 ml of the serum-free medium, the culture broth was incubated for 6 days. The culture broth was collected and centrifuged at 10,000 rpm for 15 minutes to obtain a culture supernatant that contain the target antibody. After the addition of sodium azide to final concentration 0.1 %, the culture supernatant was stored at 4 °C. 100 ml of the solution containing the antibody that was obtained was 5-fold diluted with PBS and adsorbed in a Protein G column (5 ml bed, Pharmacia) and washed with 3-bed volume of PBS. Then eluted with citrate buffer at a pH 3, the antibody fraction was recovered, and monoclonal antibody produced by each hybridoma was obtained. The monoclonal antibodies originating from the four hybridoma clones were evaluated according to the OIA method described in Publication of International Patent Application Japanese Laid-open (Toku-Hyou) No. 509565/1995.

Specifically, the OIA method comprises preparing a reactive substrate by reacting an antibody for

capture on a silicon wafer having a thin film layer of silicon nitride, causing this substrate to react with an antigen which is an extract of microorganisms for a prescribed period of time, causing the captured antigen to react with an antibody (an amplification reagent) which is an enzyme-labeled antibody, and finally adding a substrate solution to produce a thin-film precipitate. The antigen-antibody reaction can be judged visually by a degree of light interference color produced in the precipitate.

The monoclonal antibody preparation was used and evaluated as a capture antibody to be immobilized on a silicon wafer having a silicon nitride thin film layer in the OIA method. Moreover, peroxidase-labeled AMGC-1 monoclonal antibody which can non-specifically react with ribosomal proteins L7/L12 protein of a variety of microorganisms described in Reference Example was used as the detect antibody. That is, enzyme labeling was performed in accordance with the method in "Analytical Biochemistry" 132 (1983), 68-73 with the reagent S-acetylthioacetic acid N-hydroxysuccinimide for binding using horseradish peroxidase (Sigma Grade VI).

In the OIA reaction, monoclonal antibody in a PBS containing 0.05 % sodium azide was diluted with 0.1 M HEPES (pH 8.0) to a concentration of 10 µg/ml and added onto a silicone wafer which has a thin film

layer of silicon nitride, 50 μ l at a time, to react for 30 minutes at room temperature, followed by washing with distilled water and use.

15 μ l of antigen solution, which had been
5 obtained by adding 0.5% Triton X-100 to culture solutions of various species of microorganisms and then extracting the solution for 5 minutes at room temperature, was added to the specimen obtained in the above-described procedure and reacted for 10
10 minutes at room temperature. Then, 15 μ l of 20 μ g/ml peroxidase-labeled AMGC1 anti-body was added and reacted for 10 minutes. After washing with distilled water, a substrate solution (KPL) was added, 15 μ l at a time, and reacted for 5 minutes at room
15 temperature. The product was washed with distilled water to judge the concentration of detection signals as an intensity of light interference by naked eyes.

As a result, as shown in Table 2 it is clear that when monoclonal antibody derived from hybridoma AMSP-
20 2 was used as the capture antibody, all strains of *Streptococcus pneumoniae* tested were detected at a sensitivity of 10^6 bacteria/ml, while reactivity of other bacteria could not be detected at a higher concentration of 10^8 bacteria/ml. Thus, the antibody
25 with specific reactivity to *Streptococcus pneumoniae* was confirmed to have been obtained by using the monoclonal antibody to ribosomal protein L7/L12.

The hybridoma AMSP-2 which produces the monoclonal antibody specific to *Streptococcus pneumoniae* has been deposited with National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry, Japan, on July 28, 1999, with the disposition number FERM BP-6807.

Table 2

Results of Detection (10 ⁶ cells/ml)		
<i>Streptococcus pneumoniae</i>	ATCC27336	+
<i>Streptococcus pneumoniae</i>	IID554	+
<i>Streptococcus pneumoniae</i>	IID555	+
<i>Streptococcus pneumoniae</i>	IID556	+
<i>Streptococcus pneumoniae</i>	IID557	+
<i>Streptococcus pneumoniae</i>	IID558	+
<i>Streptococcus pneumoniae</i>	IID559	+
<i>Streptococcus pneumoniae</i>	IID1603	+
Results of Detection (10 ⁸ cells/ml)		
<i>Escherichia coli</i>	ATCC25922	-
<i>Enterococcus faecalis</i>	ATCC19433	-
<i>Haemophilus influenzae</i>	ATCC10211	-
<i>Klebsiella pneumoniae</i>	ATCC13883	-
<i>Neisseria gonorrhoeae</i>	IID821	-
<i>Neisseria lactamica</i>	ATCC23970	-
<i>Neisseria meningitides</i>	ATCC13090	-
<i>Pseudomonas aeruginosa</i>	ATCC27853	-
<i>Group B streptococcus</i>	ATCC12386	-
<i>Staphylococcus aureus</i>	ATCC25923	-
<i>Streptococcus pyogenes</i>	ATCC19615	-

(+: Positive; -: Negative)

Example 7

Cloning of ribosomal protein L7/L12 genes from
Neisseria gonorrhoeae, mass expression in *Escherichia*
coli and purification of the same protein and
5 preparation of monoclonal antibody to the same
protein

After inoculating an appropriate amount of
Neisseria gonorrhoeae strain IID821 (obtained from
Tokyo University School of Medicine Laboratories) in
10 a chocolate agar culture medium, the strain was
cultivated for 24 hours in a CO₂ incubator under
conditions of 37 °C and 0.5 <5.0> % CO₂. The colonies
that grew were suspended in a TE buffer to a final
concentration of approximately 5 x 10⁹ CFU/ml.

15 Approximately 1.5 ml of this suspension was
transferred to a microcentrifugation tube and
centrifuged for 2 minutes at 10,000 rpm. The
supernatant was discarded. The sediment was
resuspended in 567 µl TE buffer. Then 30 µl 10 % SDS
20 and 3 µl 20 mg/ml Proteinase K solution were added
and thoroughly mixed. The suspension was incubated
for another hour at 37 °C.

Next, after adding 80 µl 10 % cetyl trimethyl
ammonium bromide/0.7 M NaCl solution and thoroughly
25 mixing the product, it was incubated for 10 minutes
at 65 °C. Next, 700 µl chloroform-isoamyl alcohol
solution at a volume ratio of 24:1 was added and

stirred well. The solution was centrifuged for 5 minutes (while being kept at 4 °C) at 12,000 rpm using a microcentrifugation device and the aqueous fraction was transferred to a new microtube.

- 5 Isopropanol was added to the fraction at 0.6-times its volume and the tube was vigorously shaken to form sediment of the DNA. The white DNA sediment was scooped with a glass rod and transferred to a different microcentrifugation tube containing 1 ml 70
10 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes at 10,000 rpm and the supernatant was gently removed. Then another 1 ml 70 % ethanol was added and the product was centrifuged for 5 more minutes.

- 15 Once the supernatant had been removed, the sediment was dissolved in 100 µl TE buffer to obtain the DNA solution. The concentration of the genomic DNA solution was determined quantitatively in accordance with E5, Spectrophotometric determination
20 of the amount of DNA or RNA, "Molecular cloning: A laboratory manual," 1989, Eds. Sambrook, J., Fritsch, E.F., and Maniatis, T., Cold Spring Harbor Laboratory Press.

- PCR was performed using 10 ng of this genomic
25 DNA. PCR was performed using Taq polymerase (Takara Co., Ltd., code R001A). Then, 5 µl of a buffer attached to enzyme, 4 µl of a dNTP mixture attached

to enzyme, and 200 pmol each of synthetic oligonucleotide E shown in Sequence No. 15 of the Sequence Table and synthetic oligonucleotide F shown in Sequence No. 16 of the Sequence Table, which were
5 designed based on the ribosomal protein L7/L12 DNA sequence of *Neisseria gonorrhoeae* acquired from Internet Information (Oklahoma University, N. *Gonorrhoeae* Genome Project, disclosed genomic DNA data) because of the similarity with ribosomal
10 protein L7/L12 DNA sequence of other bacteria, were added to the enzyme to bring the final volume to 50 μ l.

This mixture was cycled 5 times with a TaKaRa PCR Thermal Cyclor 480 for 1 minute at 95 °C, 2 minutes
15 at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed in 1.5 % agarose gel using some of this PCR product. This product was then stained with ethidium bromide
20 (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp cDNA. After digestion treatment with restriction endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with
25 ethidium bromide was carried out. An approximately 370 bp band was cut out from the gel. This band was purified with Suprec01 (Takara Co., Ltd.) and then

inserted into pGEX-4T-1 (Pharmacia), which is a commercial vector. Actually, vector pGEX-4T-1 and the previous DNA were mixed together at a molar ratio of 1:3 and DNA was inserted into the vector with T4 DNA
5 ligase (Invitrogen Co.). Vector pGEX-4T-1 into which DNA had been inserted was genetically introduced to *Escherichia coli* One-Shot Competent Cells (Invitrogen Co., Ltd.) and then inoculated in a plate of L-Broth (Takara Co., Ltd.) semi-solid culture plate containing
10 50 µg/ml ampicillin (Sigma). The plate was then set aside at 37 °C for 12 hours and the colonies that grew were selected at random and inoculated into 2ml L-Broth liquid culture medium containing the same concentration of ampicillin. Shake cultivation was
15 performed at 37°C for 8 hours and the bacteria was recovered and the plasmid was separated using Wizard Miniprep in accordance with the attached literature. The plasmid was cleaved with restriction endonuclease BamHI/XhoI. Insertion of said PCR product was
20 confirmed by cutting out approximately 370 bp DNA. The base sequence of the DNA that had been inserted was determined using said clone.

Determination of the base sequence of the inserted DNA fragment was performed using the
25 Fluorescence Sequencer of Applied Biosystems. The sequence sample was prepared using PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied

Biosystems). First, 9.5 μ l reaction stock solution, 4.0 μ l T7 promoter primer at 0.8 pmol/ μ l (Gibco BRL) and 6.5 μ l template DNA for sequencing at 0.16 μ g/ μ l were added to a microtube with a capacity of 0.5 ml and mixed. After layering with 100 μ l mineral oil, PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 4 minutes at 60 °C. The product was then kept at 4 °C for 5 minutes. After the reaction was completed, 80 μ l sterilized pure water was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with phenol-chloroform. Ten microliters 3 M sodium acetate (pH 5.2) and 300 μ l ethanol were added to 100 μ l aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing sample. The sequencing sample was dissolved in formamide containing 4 μ l 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and submitted to sequencing. One of the 5 clones obtained had homology of the sequence with the probe used for PCR. In addition, DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example,

Haemophilus influenzae, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence No. 21 and No. 22 of the Sequence Table.

5 This gene fragment clearly codes for ribosomal protein L7/L12 gene of *Neisseria gonorrhoeae*.

Neisseria gonorrhoeae fusion GST ribosome protein L7/L12 prepared by the same method as in Example 2 was obtained using the *Neisseria gonorrhoeae* fusion
10 GST ribosomal protein L7/L12 expression vector constructed in this way.

Furthermore, hybridoma strain GCRB-3, which produces monoclonal antibody to ribosomal protein L7/L12 of *Neisseria gonorrhoeae*, was obtained in
15 accordance with the method in Example 3.

Example 8

Reaction of monoclonal antibody that reacts with ribosomal protein L7/L12 of *Neisseria gonorrhoeae*, with *Neisseria gonorrhoeae* and other microorganisms

20 Monoclonal antibody was produced and recovered in accordance with standard methods using the positive hybridoma cells GCRB-3 obtained as previously described.

Basically, 5×10^6 cells (in PBS) that had been
25 subcultured using RPMI 1640 culture medium (containing 10 % FCS) were intraperitoneally injected into Balb/C mice that had been intraperitoneally

injected with 0.5 ml Pristane 2 weeks earlier.
Ascites was recovered 3 weeks later and the
centrifugation supernatant was obtained.

The solution containing antibody that was
5 obtained was adsorbed in a Protein A column (5 ml
bed, Pharmacia) and washed with 3-bed volume of PBS.
Then eluted with citrate buffer at pH 3, the antibody
fraction was recovered and the monoclonal antibody
that was produced by each hybridoma was obtained.
10 The monoclonal antibody derived from the GCRB-3
hybridoma was used in ELISA.

The sandwich assay method was used to assess the
monoclonal antibody. The monoclonal antibody that
was prepared was used as an enzyme-labeled antibody
15 by being chemically bound to peroxidase. That is,
enzyme labeling was performed in accordance with the
method in "Analytical Biochemistry" 132 (1983), 68-73
with the reagent S-acetylthioacetic acid N-
hydroxysuccinimide for binding using horseradish
20 peroxidase (Sigma Grade VI). By means of the ELISA
reaction, a solution of commercial anti-*Neisseria*
gonorrhoeae polyclonal antibody in PBS containing
0.05% sodium azide (Virostat, rabbit) was diluted to a
concentration of 10 µg/ml and poured, 100 µl at a
25 time, into a separate 96-well plate and adsorbed
overnight at 4 °C.

After removal of the supernatant, 200 µl 1 %

bovine serum albumin solution (in PBS) were added and reacted for 1 hour and blocked at room temperature.

The supernatant was removed and the product was washed with washing solution (0.02 % Tween 20, PBS).

5 One-hundred microliters of antigen solution, which had been obtained by adding Triton X-100 to culture solutions of each species of microorganisms to a concentration of 0.3 % and then extracting the solution for 5 minutes at room temperature, were
10 added to this and reacted for 2 hours at room temperature. The supernatant was removed and the product was further washed with washing solution. Then 100 μ l peroxidase-labeled anti-ribosomal protein L7/L12 antibody solution at 5 μ g/ml were added and
15 reacted for 1 hour at room temperature. The supernatant was removed and the product was washed with washing solution. TMB (KPL) solution was added, 100 μ l at a time, and reacted for 20 minutes at room temperature. After coloration, 100 μ l 1 N sulfuric
20 acid were added to stop the reaction. Absorbance at 450 nm was determined.

As a result, as shown in Table 3 it is clear that when monoclonal antibody derived from hybridoma GCRB-3 was used as the enzyme-labeled antibody, all
25 strains of *Neisseria gonorrhoeae* tested were detected at a sensitivity of 10^6 cells/ml, while reactivity of other species belonging to the genus *Neisseria* and

other microorganisms could not be detected, even at high concentrations of 10^8 cells/ml and therefore, antibody with specific reactivity to *Neisseria gonorrhoeae* can be obtained by using monoclonal antibody to ribosomal protein L7/L12.

Table 3

Results of Detection (10^6 cells/ml)		
<i>Neisseria gonorrhoeae</i>	ATCC9793	+
<i>Neisseria gonorrhoeae</i>	ATCC19424	+
<i>Neisseria gonorrhoeae</i>	ATCC27628	+
<i>Neisseria gonorrhoeae</i>	ATCC27629	+
<i>Neisseria gonorrhoeae</i>	ATCC27630	+
<i>Neisseria gonorrhoeae</i>	ATCC27631	+
<i>Neisseria gonorrhoeae</i>	ATCC27632	+
<i>Neisseria gonorrhoeae</i>	ATCC27633	+
<i>Neisseria gonorrhoeae</i>	ATCC35541	+
<i>Neisseria gonorrhoeae</i>	ATCC35542	+
<i>Neisseria gonorrhoeae</i>	ATCC43069	+
<i>Neisseria gonorrhoeae</i>	ATCC43070	+
<i>Neisseria gonorrhoeae</i>	ATCC49226	+
Results of Detection (10^8 cells/ml)		
<i>Neisseria meningitidis</i>	ATCC13090	-
<i>Neisseria lactamica</i>	ATCC30011	-
<i>Neisseria mucosa</i>	ATCC35611	-
<i>Neisseria sicca</i>	ATCC9913	-
<i>Branhamella catarrharis</i>	ATCC25240	-
<i>Haemophilus influenzae</i>	ATCC10211	-
<i>Escherichia coli</i>	ATCC25922	-
<i>Klebsiella pneumoniae</i>	ATCC13883	-

10 (+: Positive; -: Negative)

Example 9

Acquisition of ant-ribosomal protein L7/L12 monoclonal antibody specific to genus *Neisseria*

5 After inoculating an appropriate amount of
Neisseria gonorrhoeae strain IID821 (obtained from
Tokyo University School of Medicine Laboratories) in
a chocolate agar culture medium, the strain was
cultivated for 24 hours in a CO₂ incubator under
10 conditions of 37 °C and 0.5 <5.0> % CO₂. The colonies
that grew were suspended in a TE buffer to a final
concentration of approximately 5 x 10⁹ CFU/ml.
Approximately 1.5 ml of this suspension was
transferred to a microcentrifugation tube and
15 centrifuged for 2 minutes at 10,000 rpm. The
supernatant was discarded. The sediment was
resuspended in 567 µl TE buffer. Then 30 µl 10 % SDS
and 3 µl 20 mg/ml Proteinase K solution were added
and thoroughly mixed. The suspension was incubated
20 for another hour at 37 °C. Next, after adding 80 µl
10 % cetyl trimethyl ammonium bromide/0.7 M NaCl
solution and thoroughly mixing the product, it was
incubated for 10 minutes at 65 °C. Next, 700 µl
chloroform-isoamyl alcohol solution at a volume ratio
25 of 24:1 was added and stirred well.

The solution was centrifuged for 5 minutes (while
being kept at 4 °C) at 12,000 rpm using a

microcentrifugation device and the aqueous fraction was transferred to a new microtube. Isopropanol was added to the fraction at 0.6-times its volume and the tube was vigorously shaken to form sediment of the DNA. The white DNA sediment was scooped with a glass rod and transferred to a different microcentrifugation tube containing 1 ml 70 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes at 10,000 rpm and the supernatant was gently removed. Then another 1 ml 70 % ethanol was added and the product was centrifuged for 5 more minutes. Once the supernatant had been removed, the sediment was dissolved in 100 µl TE buffer to obtain the DNA solution. The concentration of the genomic DNA solution was determined quantitatively in accordance with E5, Spectrophotometric determination of the amount of DNA or RNA, "Molecular cloning: A laboratory manual," 1989, Eds. Sambrook, J., Fritsch, E.F., and Maniatis, T., Cold Spring Harbor Laboratory Press.

PCR was performed using 10 ng of this genomic DNA. Taq polymerase (Takara Co., Ltd., code R001A) was employed for PCR. Then, 5 µl buffer attached to enzyme, 4 µl dNTP mixture attached to enzyme, and 200 pmol each of synthetic oligonucleotide E shown in Sequence No. 15 of the Sequence Table and synthetic

oligonucleotide F shown in Sequence No. 16 of the Sequence Table, which were designed based on the ribosomal protein L7/L12 DNA sequence of *Neisseria gonorrhoeae* acquired from Internet information

5 (Oklahoma University, *N. Gonorrhoeae* Genome Project, disclosed genome DNA data) because of the similarity with ribosomal protein L7/L12 DNA sequence of other bacteria, were added to the enzyme to bring the final volume to 50 μ l.

10 This mixture was cycled 5 times with a TaKaRa PCR Thermal Cycler 480 for 1 minute at 95 °C, 2 minutes at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed

15 in 1.5 % agarose gel using some of this PCR product. This product was then stained with ethidium bromide (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp cDNA. After digestion treatment with restriction

20 endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with ethidium bromide was carried out. An approximately 370 bp band was cut out from the gel. This band was purified with Suprec01 (Takara Co., Ltd.) and then

25 inserted into pGEX-6P-1 (Pharmacia), which is a commercial vector. This same vector can function as an expression vector for the desired molecule, which

can express fused protein with GST protein, by
insertion of the desired gene fragment into the
appropriate restriction endonuclease site. Actually,
vector pGEX-6P-1 and the previous DNA were mixed
5 together at a molar ratio of 1:5 and DNA was inserted
into the vector with T4 DNA ligase (Invitrogen Co.).
Vector pGEX-6P-1 into which DNA had been inserted was
genetically introduced to *Escherichia coli* One-Shot
Competent Cells (Invitrogen Co., Ltd.) and then
10 inoculated in a plate of L-Broth (Takara Co., ltd.)
semi-solid culture plate containing 50 µg/ml
ampicillin (Sigma). The plate was then set aside at
37 °C for 12 hours and the colonies that grew were
selected at random and inoculated into 2 ml L-Broth
15 liquid culture medium containing the same
concentration of ampicillin. Shake cultivation was
performed at 37 °C for 8 hours and the bacteria was
recovered and the plasmid was separated using Wizard
Miniprep in accordance with the attached literature.
20 The plasmid was cleaved with restriction endonuclease
BamHI/XhoI. Insertion of said PCR product was
confirmed by cutting out approximately 370 bp DNA.
The base sequence of the DNA that had been inserted
was determined using said clone.

25 Determination of the base sequence of the
inserted DNA fragment was performed using the
Fluorescence Sequencer of Applied Biosystems. The

sequence sample was prepared using PRISM, Ready
Reaction Dye Terminator Cycle Sequencing Kit (Applied
Biosystems). First, 9.5 µl reaction stock solution,
4.0 µl T7 promoter primer at 0.8 pmol/µl (Gibco BRL)
5 and 6.5 µl template DNA for sequencing at 0.16 µg/µl
were added to a microtube with a capacity of 0.5 ml
and mixed. After layering with 100 µl mineral oil,
PCR amplification was performed for 25 cycles, where
one cycle consisted of 30 seconds at 96 °C, 15
10 seconds at 55 °C, and 4 minutes at 60 °C. The product
was then kept at 4 °C for 5 minutes. After the
reaction was completed, 80 µl sterilized pure water
was added and stirred. The product was centrifuged
and the aqueous layer was extracted 3 times with
15 phenol-chloroform. Ten microliters 3 M sodium
acetate (pH 5.2) and 300 µl ethanol were added to 100
µl the aqueous layer and stirred. The product was
then centrifuged for 15 minutes at room temperature
and 14000 rpm and the sediment was recovered. Once
20 the sediment was washed with 75 % ethanol, it was
dried under a vacuum for 2 minutes to obtain the
sequencing sample. The sequencing sample was
dissolved in formamide containing 4 µl 10 mM EDTA and
denatured for 2 minutes at 90 °C. This was then
25 cooled in ice and submitted to sequencing.

One of the 4 clones obtained had homology of the
sequence with the probe used for PCR. In addition,

DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example, *Haemophilus influenzae*, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence ID No. 21 and No. 22 of the Sequence Table. This gene fragment clearly codes for *Neisseria gonorrhoeae* ribosomal protein L7/L12.

50 ml *Escherichia coli* into which expression vector had been inserted was cultivated overnight in a two-fold concentration YT medium at 37 °C. Then, 450ml of the two-fold concentration YT medium was heated at 37 °C for 1 hour. 50 ml of the *Escherichia coli* solution that had been cultivated overnight was introduced to 450ml of the aforementioned medium. After cultivation for one hour at 37 °C, 100 µl 500 mM IPTG was introduced and cultivated for 4 hours at 25 °C. The product was then recovered and introduced 250 ml each to a centrifugation tube and centrifuged for 20 minutes at 5000 rpm. The supernatant was discarded and dissolved in 25 ml each 50 mM Tris-HCl at a pH of 7.4 and Lysis buffer containing 25 % sucrose.

Furthermore, 1.25 ml 10% NP-40 and 125 µl 1 M MgCl₂ were added and transferred to a plastic tube. Sonication was performed 1 minute x 5 times while ice

cold. The product was centrifuged for 15 minutes at 12,000 rpm and the supernatant was recovered.

Next, the aforementioned supernatant was adsorbed on a glutathione sepharose column (manufactured by Pharmacia) conditioned with PBS. Then, the column was washed with PBS three times the bed volume. Elution was performed with 50 mM Tris-HCl at a pH of 8.0 containing 10 mM glutathione. The protein content in the fraction was determined by the pigment bonding method (Bradford method; BioRad Co.) and the main fraction was acquired. The main fraction was dialyzed three times against 3L PBS.

1 ml of a cleavage buffer containing 500 mM Tris-HCl (pH 7.0), 1.5 M NaCl, 10 mM EDTA, and 10 mM DTT was added to 10 ml of 1 mg/ml solution of the resulting GST fusion ribosomal protein L7/L12. 100 μ l of 2 u/ μ l PreScission Protease (manufactured by Pharmacia company) was further added and reacted at 4 $^{\circ}$ C to separate the GST moiety from ribosomal protein L7/L12.

The reaction solution was passed through a glutathione sepharose column which had been conditioned with PBS. The solution coming out from the column was recovered. One bed volume of PBS was passed through and also recovered. Purity of the purified ribosomal protein L7/L12 that was obtained was confirmed by electrophoresis to be approximately

90 %, showing that a purity satisfactory for an immunogen could be guaranteed.

First, 100 µg protein antigen of ribosomal protein L7/L12 of *Neisseria gonorrhoeae* was dissolved in 200 µl PBS and then 200 µl Freund's complete adjuvant was added and mixed and emulsification was performed. 200 µl was intraperitoneally injected to immunize mice. Then, the same emulsion antigen was intraperitoneally injected after 2 weeks, after 4 weeks, and after 6 weeks. A two-fold concentration antigen emulsion was further injected intraperitoneally after 10 weeks and after 14 weeks. The spleen was excised 3 days after the final immunization and submitted to cell fusion.

After thoroughly mixing 2×10^7 myeloma cells per 10^8 spleen cells from mice, which had been recovered aseptically, in a glass tube, the mixture was centrifuged for 5 minutes at 1500 rpm and the supernatant was discarded. The cells were thoroughly mixed.

The myeloma cells used for cell fusion were obtained by cultivation of cell strain NS-1 with an RPMI 1640 culture medium containing 10 % FCS, cultivating this product beginning 2 weeks before cell fusion using an RPMI 1640 medium containing 0.13 mM azaguanine, 0.5 µg/ml MC-210, and 10 % FCS for 1 weeks, and then further cultivating the cell strain

for 1 week with an RPMI 1640 medium containing 10 %
FCS. 30 ml of RPMI 1640 culture medium 50 ml that had
been kept at 37°C was added to the mixed cell sample
and centrifuged at 1,500 rpm. After removal of the
5 supernatant, 1 ml 50 % polyethylene glycol that had
been kept at 37 °C was added and stirred for 2 minute.
10 ml RPMI 1640 medium kept at 37 °C was added and
the solution was vigorously mixed for approximately 5
minutes as it was suctioned and evacuated from a
10 sterile pipette.

After centrifugation for 5 minutes at 1,000 rpm
and removal of the supernatant, 30 ml HAT culture
medium were added to bring the cell concentration to
5 x 10⁶ cells/ml. This mixture was stirred till
15 uniform and then poured, 0.1 ml at a time, into a 96-
well culture plate and cultivated at 37 °C under 7 %
CO₂. HAT medium was added, 0.1 ml at a time, on Day 1
and at Week 1 and Week 2.

Then the cells that had produced the desired
20 antibody were assessed by ELISA. Solutions of
ribosomal protein L7/L12 of *Neisseria gonorrhoeae*
dissolved in PBS containing 0.05 % sodium azide were
diluted to 10 µg/ml and were poured, 100 µl at a time,
into separate 96-well plates and adsorbed overnight
25 at 4 °C. After removal of the supernatant, 200 µl 1 %
bovine serum albumin solution (in PBS) were added and
reacted and blocked for 1 hour at room temperature.

The supernatant was removed and the product was washed with a washing solution (0.02 % Tween 20, PBS). 100 μ l of a culture solution of fusion cells was added and reacted for two hours at room temperature.

5 The supernatant was removed and the product was further washed with a washing solution. Then, 100 μ l of a peroxidase-labeled goat anti-mouse antibody solution at 50 ng/ml was added and reacted for one hour at room temperature. The supernatant was removed and the product was washed with a washing solution. TMB (KPL) solution was added, 100 μ l at a time, and reacted for 20 minutes at room temperature. After coloration, 100 μ l 1 N sulfuric acid were added to stop the reaction. Absorbance at 450 nm was
10 determined.
15

As a result, positive wells that reacted with ribosomal protein L7/L12 were detected, confirming presence of the antibody to ribosomal protein L7/L12.

Therefore, the cells in the positive wells were recovered and cultivated with HAT medium in a 24-well plastic plate. The fused medium that had been
20 cultivated was diluted with an HT medium to a cell count of approximately 20 cells/ml. Then 50 μ l the medium was mixed with 10^6 six-week-old mouse thyroid
25 cells suspended in the HT medium in a 96-well culture plate. The cells were cultivated for 2 weeks at 37 °C under the conditions of 7 % CO₂. The antibody titer in

the culture supernatant was determined by the
aforementioned ELISA method and, the cells those
showed a positive reaction with ribosomal protein
L7/L12 were recovered. Furthermore, the same dilution
5 and cloning procedure was repeated to obtain a total
of 4 clones of hybridoma AMGC-5 to AMGC-8.

Monoclonal antibody was produced and recovered
according to standard methods, using the positive
hybridoma cells obtained as previously described.

10 Specifically, cells subcultured in RPMI 1640
medium (containing 10 % FCS) was diluted in serum-
free medium to about 2×10^5 cells/ml, 3.3×10^5
cells/ml, and 5×10^5 cells/ml in 25 cm² culture flask,
and the total was made 5 ml. After cells were grown
15 for 3 to 5 days in 7 % CO₂ at 37 °C, flask that
contains the least number of original cells was
selected among flasks in which cells were grown. The
same procedure was repeated until the cells diluted
to 2×10^5 cells/ml grow to 2×10^6 cells/ml in 3 to 4
20 days, thereby adapting the cells with serum-free
medium. Next, cloning was performed in a 96-well
plate for bacterial culture to select cells
exhibiting fastest growth and a highest antibody
titer. The selected cells were grown in a 24-well
25 plate and diluted with a serum-free medium in a 25
cm² culture flask to a concentration of about 2×10^5
cells/ml and the total volume was made to 10 ml.

After incubation for 3 to 4 days in 7 % CO₂ at 37 °C to a concentration of 1 x 10⁶ cells/ml, the culture broth 100 ml, 1 x 10⁶ cells/ml was transferred to a bottle for mass cultivation which were grown in the same manner in a 75 cm² flask. 100 ml of a serum-free medium was added to the mixture and was incubated at 37 °C for two days while stirring. 200 ml of the serum-free medium was added again and the mixture was incubated for a further two days. The culture broth was divided into four aliquots, one volume serum-free medium was added to each portion, followed by incubation for two days. After further addition of 400 ml of the serum-free medium, the culture broth was incubated for 6 days. The culture broth was collected and centrifuged at 10,000 rpm for 15 minutes to obtain culture supernatant containing the target antibody. After adding sodium azide to final concentration 0.1 %, the culture supernatant was stored at 4 °C. 100 ml of the supernatant containing the antibody was diluted 5-fold with PBS and adsorbed in a protein G column (5 ml bed, Pharmacia) and washed with 3-bed volume of PBS. Then eluted with citrate buffer at pH 3, the antibody fraction was recovered and monoclonal antibody produced by each hybridoma was obtained.

The monoclonal antibodies originating from the four hybridoma clones were evaluated according to the

OIA method described in International Patent
Application Japanese Laid-open No. 509565/1995.

Specifically, the OIA method comprises preparing
a reactive substrate by reacting an antibody for
5 capture on a silicon wafer having a thin film layer
of silicon nitride, causing this substrate to react
with an antigen which is an extract of microorganisms
for a prescribed period of time, causing the captured
antigen to react with an antibody (an amplification
10 reagent) which is an enzyme-labeled antibody, and
finally adding a substrate solution to produce a
thin-film precipitate. The antigen-antibody reaction
can be judged visually by a degree of light
interference color produced in the precipitate.

15 The monoclonal antibody preparation was used as a
capture antibody to be immobilized on a silicon wafer
having a silicon nitride thin film layer in the OIA
method. Moreover, peroxidase-labeled AMGC-1
monoclonal antibody which can non-specifically react
20 with ribosomal proteins L7/L12 protein of a variety
of microorganisms described in Reference Example was
used as the detect antibody. That is, enzyme
labeling was performed in accordance with the method
in "Analytical Biochemistry" 132 (1983), 68-73 with
25 the reagent S-acetylthioacetic acid N-
hydroxysuccinimide for binding using horseradish
peroxidase (Sigma Grade VI).

In the OIA reaction, monoclonal antibody in a PBS containing 0.05 % sodium azide was diluted with 0.1 M HEPES (pH 8.0) to a concentration of 10 µg/ml and added onto a silicone wafer which has a thin film layer of silicon nitride, 50 µl at a time, to react for 30 minutes at room temperature, followed by washing with distilled water and use. 15 µl of antigen solution, which had been obtained by adding 0.5 % Triton X-100 to culture suspension of various species of microorganisms and then extracting the suspension for 5 minutes at room temperature, was added to the specimen obtained in the above-described procedure and reacted for 10 minutes at room temperature. Then, 15 µl of 20 µg/ml peroxidase-labeled AMGC1 was added and reacted for 10 minutes. After washing with distilled water, a substrate solution (KPL Co.) was added, 15 µl at a time, and reacted for 5 minutes at room temperature. The product was washed with distilled water to judge the concentration of detection signals as an intensity of light interference by naked eyes.

As a result, as shown in Table 4 it is clear that when monoclonal antibody derived from hybridoma AMGC-8 was used as the capture antibody, all strains of *Neisseria* genus tested were detected at a sensitivity of 10^8 cells/ml, while reactivity of other microorganisms could not be detected. Thus, the

antibody with specific reactivity to *Neisseria* genus was confirmed to have been obtained by using the monoclonal antibody to ribosomal protein L7/L12.

5 Table 4

Results of Detection (10 ⁸ cells/ml)		
<i>Neisseria gonorrhoeae</i>	IID821	+
<i>Neisseria lactamica</i>	ATCC23970	+
<i>Neisseria meningitidis</i>	ATCC13090	+
<i>Escherichia coli</i>	ATCC25922	—
<i>Enterococcus faecalis</i>	ATCC19433	—
<i>Haemophilus influenzae</i>	ATCC10211	—
<i>Klebsiella pneumoniae</i>	ATCC13883	—
<i>Pseudomonas aeruginosa</i>	ATCC27853	—
<i>Group B streptococcus</i>	ATCC12386	—
<i>Staphylococcus aureus</i>	ATCC25923	—
<i>Streptococcus pneumoniae</i>	ATCC27336	—
<i>Streptococcus pyogenes</i>	ATCC19615	—

(+: Positive; -: Negative)

10 Example 10

Acquisition of a polyclonal antibody which specifically reacts with ribosomal protein L7/L12 of *Haemophilus influenzae* using a ribosomal protein L7/L12 protein-immobilized affinity column

15 A centrifugal supernatant of *Haemophilus influenzae* cell extract, which had been treated with 0.5% Triton X-100 was used as an antigen. About 1.2 ml of a physiological saline solution containing 100

µg of antigen was emulsified with the addition of 1.5 ml of Freund's adjuvant. The emulsion was subcutaneously injected into four SPF Japanese White Rabbits to immunize the animals. The rabbits were immunized 5 to 6 times, once every two weeks, and the antibody titer was confirmed.

The antibody titer was confirmed by the ELISA method. Solutions of ribosomal protein L7/L12 of *Haemophilus influenzae* dissolved in PBS containing 0.05 % sodium azide diluted to 10 µg/ml were poured, 100 µl at a time, into 96-well plates and adsorbed overnight at 4 °C. After removal of the supernatant, 200 µl 1 % bovine serum albumin solution (in PBS) were added and reacted and blocked for 1 hour at room temperature. The supernatant was removed and the product was washed with a washing solution (0.02 % Tween 20, PBS). 100 µl of a solution obtained by diluting normal rabbit serum and immunized rabbit antiserum was added and reacted for two hours at room temperature. The supernatant was removed and the product was further washed with a washing solution. Then, 100 µl of a peroxidase-labeled goat anti-rabbit IgG antibody solution at 50 ng/ml was added and reacted for one hour at room temperature. The supernatant was removed and the product was washed with a washing solution. OPD solution (Sigma Co.) was added, 100 µl at a time, and reacted for 20

minutes at room temperature. After coloration, 100 μ l of 1 N sulfuric acid was added to stop the reaction. Absorbance at 492 nm was determined.

After confirming that the antibody titer had increased, a large quantity of blood was collected. Blood was collected in a centrifugal tube made of glass from the ear artery, allowed to stand for one hour at 37 °C, then overnight at 4 °C. The mixture was centrifuged at 3000 rpm for 5 minutes and the supernatant was recovered. The resulting 4 lots of anti-serum were stored at 4 °C.

Next, an affinity column with immobilized ribosomal protein L7/L12 of *Haemophilus influenzae* and *Neisseria gonorrhoeae* was prepared. HiTrap NHS-activated column (1 ml, manufactured by Pharmacia) was used. Immediately after replacing the column with 6 ml of 1 mM HCl, 1 ml of a PBS solution of ribosomal protein L7/L12 adjusted to 1 mg/ml was charged. The column was allowed to stand for 15 minutes at 25 °C. This procedure was repeated 5 times, thereby feeding the total 5 ml of the PBS solution of ribosomal protein L7/L12. Then, 6 ml of Buffer A (0.5 M ethanolamine, 0.5 M NaCl, pH 8.3), 6 ml of Buffer B (0.1 M acetic acid, 0.5 M NaCl, pH 4), and 6 ml of Buffer A were charged as blocking reagents. After allowing to stand for 15 minutes at 25 °C, 6 ml of Buffer B, 6 ml of Buffer A, and 6 ml

of Buffer B were further added. The mixture was then equilibrated with 6 ml of PBS.

Using the affinity column with immobilized ribosomal protein L7/L12 of *Haemophilus influenzae*, the polyclonal antibody in the resulting anti-serum was purified using the supernatant of Triton X-100 treated bacteria of *Haemophilus influenzae* as an antigen. This antiserum was first diluted with PBS to a volume of 5 times, passed through a 0.45 μ m filter, then caused to be adsorbed in the column immobilized with ribosomal protein L7/L12 of *Haemophilus influenzae* at a flow rate of 0.5 ml/min. After elution from the column with 0.1 M glycine (pH 2.1) and immediately neutralizing with 1 M Tris-HCl (pH 9.0), eluted fractions of the target antibody were recovered by the ELISA method, the same as anti-titer measuring method. These fractions were passed through the affinity column immobilized with the ribosomal protein L7/L12 of *Neisseria gonorrhoeae*, which was equilibrated with PBS whereby the antibody that reacts with the ribosomal protein L7/L12 of *Neisseria gonorrhoeae* was adsorbed and fraction which passed through without adsorption was recovered.

The polyclonal antibody purified in this manner was evaluated by the same OIA method as in Example 6.

The purified antibody was used as a capture antibody for the OIA method. Moreover, peroxidase-

labeled AMGC-1 monoclonal antibody described in Reference Example was used as the detect antibody. That is, enzyme labeling was performed in accordance with the method in "Analytical Biochemistry" 132 (1983), 68-73 with the reagent S-acetylthioacetic acid N-hydroxysuccinimide for binding using horseradish peroxidase (Sigma Grade VI).

In the OIA reaction, the purified polyclonal antibody in a PBS containing 0.05 % sodium azide was diluted with 0.1 M HEPES (pH 8.0) to a concentration of 10 µg/ml and added onto a silicone wafer, 50 µl at a time, to react for 30 minutes at room temperature, followed by washing with distilled water and use.

15 µl of antigen solution, which had been obtained by adding 0.5 % Triton X-100 to culture suspension of various species of microorganisms and then extracting the suspension for 5 minutes at room temperature, was added to the specimen obtained in the above-described procedure and reacted for 10 minutes at room temperature. Then, 15 µl of 20 µg/ml peroxidase-labeled AMGC1 was added and reacted for 10 minutes. After washing with distilled water, a substrate solution (KPL) was added, 15 µl at a time, and reacted for 5 minutes at room temperature. The product was washed with distilled water to observe the blue color concentration by the naked eyes.

As a result, as shown in Table 5 it is clear that

when the purified polyclonal antibody of APhi2-2 was used as the capture antibody, *Haemophilus influenzae* tested at a sensitivity of 10^8 bacteria/ml was detected, while reactivity of other microorganisms could not be detected. Thus, the antibody with specific reactivity to *Haemophilus influenzae* was confirmed to have been obtained by using the polyclonal antibody purified by an affinity column immobilized with the ribosomal protein L7/L12 of *Haemophilus influenzae*.

Table 5

Results of Detection (10^8 cells/ml)		
<i>Haemophilus influenzae</i>	ATCC10211	+
<i>Escherichia coli</i>	ATCC25922	—
<i>Enterococcus faecalis</i>	ATCC19433	—
<i>Klebsiella pneumoniae</i>	ATCC13883	—
<i>Neisseria gonorrhoeae</i>	IID821	—
<i>Neisseria lactamica</i>	ATCC23970	—
<i>Neisseria meningitidis</i>	ATCC13090	—
<i>Pseudomonas aeruginosa</i>	ATCC27853	—
GroupB <i>Streptococcus</i>	ATCC12386	—
<i>Staphylococcus aureus</i>	ATCC25923	—
<i>Streptococcus pneumoniae</i>	ATCC27336	—
<i>Streptococcus pyogenes</i>	ATCC19615	—

(+: Positive; -: Negative)

Reference Example 1

Acquisition of monoclonal antibody that reacts non-specifically with ribosomal protein L7/L12 of various bacteria

So called sandwich assay in which an antigen is sandwiched between a capture antibody and a labeled antibody for detection is useful to detect microorganisms by optical immunoassay and the ELISA method because of its high detection sensitivity. In this instance, not only an antibody which specifically reacts with antigens originating from the subject microorganism, but also another antibody which recognizes an antigen epitope different from that of the specific antibody are required.

Antibodies which react non-specifically with ribosomal protein L7/L12 originating various microorganisms are very useful as an antibody which can constitute a sandwich assay with an antibody which reacts specifically with ribosomal protein L7/L12.

Fortunately, ribosomal proteins L7/L12 protein of a variety of microorganisms have a region wherein the amino acid sequence is homologous. Here, the inventors have been successful in acquiring a monoclonal antibody which exhibits a cross reaction with ribosomal proteins L7/L12 protein of various species of microorganisms from *Neisseria gonorrhoeae*. It has been discovered that an antibody to anti-

ribosomal protein L7/L12 having no specificity, which was acquired from one species of microorganisms can be used for sandwich assay of several kinds of microorganisms.

5 Cloning of ribosomal protein L7/L12 genes from *Neisseria gonorrhoeae*, mass expression in *Escherichia coli* and purification of the same protein, and preparation of monoclonal antibody to the same protein were performed.

10 After inoculating an appropriate amount of *Neisseria gonorrhoeae* strain IID821 (obtained from Tokyo University School of Medicine Laboratories) in a chocolate agar culture medium, the strain was cultivated for 24 hours in a CO₂ incubator under
15 conditions of 37 °C and 0.5 <5.0> % CO₂. The colonies that grew were suspended in a TE buffer to a final concentration of approximately 5 x 10⁹ CFU/ml. Approximately 1.5 ml of this suspension was transferred to a microcentrifugation tube and
20 centrifuged for 2 minutes at 10,000 rpm. The supernatant was discarded. The sediment was resuspended in 567 µl TE buffer. Then 30 µl 10 % SDS and 3 µl 20 mg/ml Proteinase K solution were added and thoroughly mixed. The suspension was incubated
25 for another hour at 37 °C. Next, after adding 80 µl 10 % cetyl trimethyl ammonium bromide/0.7 M NaCl solution and thoroughly mixing the product, it was

incubated for 10 minutes at 65 °C. Next, 700 µl
chloroform-isoamyl alcohol solution at a volume ratio
of 24:1 was added and stirred well. The solution was
centrifuged for 5 minutes (while being kept at 4 °C)
5 at 12,000 rpm using a microcentrifugation device and
the aqueous fraction was transferred to a new
microtube. Isopropanol was added to the fraction at
0.6-times its volume and the tube was vigorously
shaken to form sediment of the DNA. The white DNA
10 sediment was scooped with a glass rod and transferred
to a different microcentrifugation tube containing 1
ml 70 % ethanol (cooled to -20 °C).

Next, the product was centrifuged for 5 minutes
at 10,000 rpm and the supernatant was gently removed.
15 Then another 1 ml 70 % ethanol was added and the
product was centrifuged for 5 more minutes. Once the
supernatant had been removed, the sediment was
dissolved in 100 µl TE buffer to obtain the DNA
solution. The concentration of the genomic DNA
20 solution was determined quantitatively in accordance
with E5, Spectrophotometric determination of the
amount of DNA or RNA, "Molecular cloning: A
laboratory manual," 1989, Eds. Sambrook, J., Fritsch,
E.F., and Maniatis, T., Cold Spring Harbor Laboratory
25 Press.

PCR was performed using 10 ng of this genomic
DNA. Taq polymerase (Takara Co., Ltd., code R001A)

was employed for PCR. Then, 5 µl of a buffer attached to enzyme, 4 µl of dNTP mixture attached to enzyme, and 200 pmol of each of synthetic oligonucleotide E shown in Sequence No. 15 of the

5 Sequence Table and synthetic oligonucleotide F shown in Sequence No. 16 of the Sequence Table, which were designed based on the ribosomal protein L7/L12 DNA sequence of *Neisseria gonorrhoeae* acquired from Internet information (Oklahoma University, N.

10 *Gonorrhoeae* Genome Project, disclosed genomic DNA data) because of the similarity with ribosomal protein L7/L12 DNA sequence of other bacteria, were added to the enzyme to bring the final volume to 50 µl.

15 This mixture was cycled 5 times with a TaKaRa PCR Thermal Cycler 480 for 1 minute at 95 °C, 2 minutes at 50 °C, and 3 minutes at 72 °C and was then cycled 25 times for 1 minute at 95 °C, 2 minutes at 60 °C, and 3 minutes at 72 °C. Electrophoresis was performed

20 in 1.5 % agarose gel using some of this PCR product.

This product was then stained with ethidium bromide (Nihon Gene Co., ltd.) and observed under ultraviolet rays to confirm amplification of approximately 400 bp cDNA. After digestion treatment with restriction

25 endonucleases BamHI and XhoI, electrophoresis was performed in 1.5 % agarose gel and staining with ethidium bromide was carried out. An approximately

370 bp band was cut out from the gel. This band was purified with Suprec01 (Takara Co., Ltd.) and then inserted into pGEX-4T-1 (Pharmacia), which is a commercial vector. Actually, vector pGEX-4T-1 and the previous DNA were mixed together at a molar ratio of 1:3 and DNA was inserted into the vector with T4 DNA ligase (Invitrogen Co.). Vector pGEX-4T-1 into which DNA had been inserted was genetically introduced to *Escherichia coli* One-Shot Competent Cells (Invitrogen Co., Ltd.) and then inoculated in a plate of L-Broth (Takara Co., Ltd.) semi-solid culture plate containing 50 µg/ml ampicillin (Sigma). The plate was then set aside at 37 °C for 12 hours and the colonies that grew were selected at random and inoculated into 2 ml L-Broth liquid culture medium containing the same concentration of ampicillin. Shake cultivation was performed at 37 °C for 8 hours and the bacteria was recovered and the plasmid was separated using Wizard Miniprep in accordance with the attached literature. The plasmid was cleaved with restriction endonuclease BamHI/XhoI. Insertion of said PCR product was confirmed by cutting out approximately 370 bp DNA. The base sequence of the DNA that had been inserted was determined using said clone.

Determination of the base sequence of the inserted DNA fragment was performed using the

Fluorescence Sequencer of Applied Biosystems. The sequence sample was prepared using PRISM, Ready Reaction Dye Terminator Cycle Sequencing Kit (Applied Biosystems). First, 9.5 μ l reaction stock solution, 4.0 μ l T7 promoter primer at 0.8 pmol/ μ l (Gibco BRL) and 6.5 μ l template DNA for sequencing at 0.16 μ g/ μ l were added to a microtube with a capacity of 0.5 ml and mixed. After superposition with 100 μ l mineral oil, PCR amplification was performed for 25 cycles, where one cycle consisted of 30 seconds at 96 °C, 15 seconds at 55 °C, and 5 minutes at 60 °C. The product was then kept at 4 °C for 4 minutes. After the reaction was completed, 80 μ l sterilized pure water was added and stirred. The product was centrifuged and the aqueous layer was extracted 3 times with phenol-chloroform. Ten microliters 3 M sodium acetate (pH 5.2) and 300 μ l ethanol were added to 100 μ l aqueous layer and stirred. The product was then centrifuged for 15 minutes at room temperature and 14,000 rpm and the sediment was recovered. Once the sediment was washed with 75 % ethanol, it was dried under a vacuum for 2 minutes to obtain the sequencing sample. The sequencing sample was dissolved in formamide containing 4 μ l 10 mM EDTA and denatured for 2 minutes at 90 °C. This was then cooled in ice and submitted to sequencing. One of the 5 clones obtained had homology of the sequence with the probe

used for PCR. In addition, DNA sequences extremely similar to the gene sequence of ribosomal protein L7/L12 gene of the other microorganisms, for example, *Haemophilus influenzae*, were discovered. The entire base sequence and the corresponding amino acid sequence of the structural gene moiety are as shown in Sequence No. 21 and No. 22 of the Sequence Table. This gene fragment clearly codes for *Neisseria gonorrhoeae* ribosomal protein L7/L12.

Neisseria gonorrhoeae GST fused ribosome protein L7/L12 prepared by the same method as in Example 2 was obtained using the *Neisseria gonorrhoeae* GST fusion ribosomal protein L7/L12 expression vector constructed in this way. Furthermore, hybridoma strain AMGCl, which produces monoclonal antibody to ribosomal protein L7/L12 of *Neisseria gonorrhoeae*, was obtained in accordance with the method similar to the method of Example 3. Monoclonal antibody was produced and recovered in accordance with standard methods using the positive hybridoma cells of AMGCl strain obtained as previously described.

Specifically, cells subcultured in RPMI 1640 medium (containing 10 % FCS) was diluted with a serum-free medium to about 2×10^5 cells/ml, 3.3×10^5 cells/ml, and 5×10^5 cells/ml in 25 cm² culture flasks, and the total was made 5 ml. After cell were grown for 3 to 5 days in 7 % CO₂ at 37 °C, a flask

which contains the least number of original cells was selected among flasks in which cells were grown. The same procedure was repeated until the cells diluted to 2×10^5 cells/ml grow to 2×10^6 cells/ml in 3 to 4 days, thereby adapting the cells with the serum-free medium. Next, cloning was performed in a 96-well plate for bacteria cultivation to select cells exhibiting fastest growth and a highest antibody titer. The selected cells were grown in a 24-well plate and diluted with a serum-free medium in a 25 cm² culture flask to a concentration of about 2×10^5 cells/ml and the total volume was made 10 ml. After incubation for 3 to 4 days in 7 % CO₂ at 37 °C to a concentration of 1×10^6 cells/ml, the culture broth 100 ml, 1×10^6 cells/ml was transferred to a bottle for mass cultivation which were grown in the same manner in a 75 cm² flask. 100 ml of a serum-free medium was added to the mixture, which was incubated at 37 °C for two days while stirring. 200 ml of the serum-free medium was added again and the mixture was incubated for a further two days. The culture broth was divided into four aliquots, the serum-free medium was added to each portion, followed by incubation for two days. After further addition of 400 ml of the serum-free medium, the culture broth was incubated for 6 days. The culture broth was collected and centrifuged at 10,000 rpm for 15 minutes to obtain a

culture supernatant including the target antibody.
After the addition of sodium azide to final
concentration 0.1 %, the culture supernatant was
stored at 4 °C. 100 ml of the solution containing the
5 antibody that was obtained was diluted 5-fold with
PBS and adsorbed in a Protein A column (5 ml bed
volume, Pharmacia) and washed with 3-bed volume of
PBS. Then eluted with citrate buffer at pH 3, the
antibody fraction was recovered and monoclonal
10 antibody produced by each hybridoma was obtained.
The monoclonal antibody derived from the hybridoma
was used in ELISA.

To evaluate the antibody, 96-well plates
sensitized with ribosomal proteins L7/L12 of various
15 microorganisms were used as an antigen. The
monoclonal antibody prepared was reacted, followed by
the reaction of horseradish peroxidase-labeled anti-
mouse IgG (manufactured by MBL, Code 330) as a
secondary antigen, and finally the antibody was
20 detected using an enzyme reaction coloring reagent.
In the ELISA reaction, solutions of recombinant
ribosomal protein L7/L12 of *Neisseria gonorrhoeae*,
Haemophilus influenzae, and *Streptococcus pneumoniae*
dissolved in PBS containing 0.05 % sodium azide
25 diluted to 1 µg/ml were poured, 100 µl at a time,
into separate 96-well plates and adsorbed overnight
at 4 °C. After removal of the supernatant, 200 µl 1%

bovine serum albumin solution (in PBS) were added and reacted and blocked for 1 hour at room temperature.

The supernatant was removed and the product was washed with a washing solution (0.02 % Tween 20,

5 PBS). Solutions of AMGC1 antibody, at concentrations of 0.1-1 µg/ml, in an amount of 100 µl each, were added and reacted for two hours at room temperature.

The supernatant was removed and the product was further washed with a washing solution. Then, 100 µl

10 of a solution of 5 µg/ml horse radish peroxidase-labeled anti-mouse IgG (manufactured by MBL, Code 330) was added and reacted for one hour at room

temperature. The supernatant was removed and the product was washed with a washing solution. TMB (KPL)

15 solution was added, 100 µl at a time, and reacted for 20 minutes at room temperature. After coloration,

100 µl 1 N sulfuric acid were added to stop the reaction. Absorbance at 450 nm was determined.

As a result, as shown in Table 6 it was confirmed

20 that when the monoclonal antibody originating from hybridoma AMGC1 was used, this antibody can react with ribosomal proteins L7/L12 of all bacteria such as *Neisseria gonorrhoeae*, *Haemophilus influenzae*, and *Streptococcus pneumoniae*.

25

Table 6

Results of detection of AMGC1 antibody and Ribosomal Protein L7/L12 of microorganisms

<i>Neisseria gonorrhoeae</i>	+
<i>Haemophilus influenzae</i>	+
<i>Streptococcus pneumoniae</i>	+

(+: Positive)

The AMGCl antibody obtained here is very useful
 5 as an antibody used for the detection of
 microorganisms in the so-called sandwich assay by
 optical immunoassay and ELISA method, in combination
 with an anti-ribosomal protein L7/L12 antibody which
 is specific to each microorganism.

10 Industrial Applicability

According to the present invention, not only
 microorganisms can be detected specifically according
 to species, but also microorganisms of all serotypes
 15 in the same species can be detected at a high
 precision, by using antibodies to intracellular
 molecules of the same function.

By using antibodies to ribosomal proteins L7/L12
 of various microorganisms as such antibodies,
 20 *Haemophilus influenzae* and *Neisseria gonorrhoeae* can
 be detected precisely.

Moreover, specific antibodies used for the
 detection of various kinds of microorganisms can be
 prepared by using intracellular molecules exhibiting
 25 same functions in various microorganisms as an

antigen.

REMARKS TO DEPOSITED MICROORGANISMS

The organization in which the microorganisms have been deposited:

- 5 National Institute of Bioscience and Human
 Technology, the Agency of Industrial Science
 and Technology

Address: 1-1-3, Higashi, Yatabe-cho, Tsukuba-shi,
 Ibaraki-ken, Japan (Postal Code: 305).

- 10 Date of deposition: July 28, 1999

Number of deposition given by the deposition
organization: FERM BP-6807

CLAIMS:

1. Antibodies which are antibodies to ribosomal protein of microorganisms and which react specifically with said microorganisms.

5 2. The antibodies according to claim 1, where the ribosomal protein of the microorganisms is ribosomal protein L7/L12.

10 3. The antibodies according to claim 1 or 2, where said microorganisms are microorganisms which cause a sexually transmitted disease (STD).

4. The antibodies according to claim 1 or 2, where said microorganisms are microorganisms which cause respiratory tract infection.

15 5. The antibody according to claim 4, where the causative microorganisms of respiratory tract infection are microorganisms of *Haemophilus influenzae*.

20 6. The antibody according to claim 4, where the causative microorganisms of respiratory tract infection are microorganisms of *Streptococcus pneumoniae*.

25 7. The antibody according to claim 3, where the causative microorganisms of sexually transmitted diseases (STD) are microorganisms of *Neisseria gonorrhoeae*.

8. The antibody according to claim 7, which is the antibody to ribosomal protein L7/L12 of *Neisseria*

gonorrhoeae and which recognizes a continuous amino acid sequence moiety from 5 to 30 amino acids including the 115th alanine in the amino acid sequence of Sequence ID No. 22 of the Sequence Table.

5 9. A method of detecting microorganisms, which is characterized by the fact that antibody to intracellular molecules that have the same function for a variety of microorganisms is used.

10 10. A method of detecting microorganisms, which is characterized by the fact that any antibody according to claims 1 to 8 is used.

15 11. A reagent kit for detecting microorganisms, which is characterized by the fact that antibody to intracellular molecules that have the same function for a variety of microorganisms is used.

 12. A reagent kit for detecting microorganisms, which is characterized by the fact that any antibody according to claims 1 to 8 is used.

20 13. A method of preparing any antibody described in any one of claims 1 to 8, characterized by the fact that ribosomal protein L7/L12 of microorganisms obtained by a gene manipulation procedure or by isolation from microorganisms, peptide moiety thereof, or a synthesized peptide corresponding to
25 the peptide moiety is used as an immunogen.

014:28228 13:25 ASAHI KASEI PAT. FUJINO PATENT ATTORNEY

NO. 5005 P. 2/4
NO. 7122 P. 4/6

ASAHI-2-PC-1

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ANTIBODIES FOR DETECTING MICROORGANISMS

the specification of which: (check one)

REGULAR OR DESIGN APPLICATION

- ☐ is attached hereto.
- ☐ was filed on _____ as application Serial No. _____ and was amended on _____ (if applicable).

PCT FILED APPLICATION ENTERING NATIONAL STAGE

- ☒ was described and claimed in International application No. PCT/JP99/04122 filed on 30 July, 1999 and as amended on _____ (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under 35 USC 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

Country	Application Number	Date of Filing (day, month, year)	Priority Claimed
Japan	10/230204	31 July 1998	Yes

(Complete this part only if this is a continuing application.)

I hereby claim the benefit under 35 USC 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status-patented, pending, abandoned)

POWER OF ATTORNEY

ASAHI-2-PC-1

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from the Patent Agency as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

As a named inventor, I hereby appoint the registered patent attorneys represented by Customer No. 000466 to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, including: Robert J. PATCH, Reg. No. 17,355, Andrew J. PATCH, Reg. No. 32,925, Robert F. HARGEST, Reg. No. 25,590, Benoit CASTEL, Reg. No. 35,041, Eric JENSEN, Reg. No. 37,865, Thomas W. PERKINS, Reg. No. 33,027, and Roland E. LONG, Jr., Reg. No. 41,949,

c/o YOUNG & THOMPSON,
Second Floor,
745 South 23rd Street,
Arlington, Virginia 22202.

00466

Address all telephone calls to Young & Thompson at 703/521-2297. Telefax: 703/685-0573.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: Kenji MATSUYAMA
(given name, family name)

Inventor's signature Kenji Matsuyama

Date 23/2/01

Residence: Sizuoka 416-0939, Japan

Citizenship: Japan

Post Office Address: 205 Kurieito Maitsu, 690-1, Kawenarijima, Fuji-shi
Sizuoka 416-0939, Japan

Full name of second joint inventor, if any: Takashi SHIRAI
(given name, family name)

Inventor's signature Takashi Shirai

Date 23/2/01

Residence: Sizuoka 411-0943, Japan

Citizenship: Japan

Post Office Address: 541-36, Shimotogari, Nagaizumicho Sento-gun
Sizuoka 411-0943, Japan

Full name of third joint inventor, if any: Takashi ETOH
(given name, family name)

Inventor's signature Takashi Etoh

Date 23/2/01

Residence: Longmont, CO 80502 U.S.A.

Citizenship: Japan

Post Office Address: #4306, 2424 9th Avenue
Longmont, CO 80502 U.S.A.